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ABSTRACT

MATTHEW JAMES SCHEFFEL. N-Acetyl Cysteine Protects Melanoma Specific Cytotoxic T
Cells from T Cell Receptor Restimulation Induced Activation of the DNA Damage Response
Pathway and Enhances Tumor Control In Vitro and In Vivo. (Under the direction of
CHRISTINA VOELKEL-JOHNSON).

The adoptive transfer of autologous melanoma antigen-specific T cells has
demonstrated a remarkable improvement in clinical outcomes for patients with latestage metastatic melanoma. However, the majority of patients do not achieve a durable
response. To achieve a sufficient quantity of cells for transfer, T cells undergo a rapid
expansion protocol which makes them more susceptible to activation-induced cell death
(AICD). As the persistence of transferred T cells is necessary for optimal patient response,
limitation of persistence via AICD is likely a constraint on clinical efficacy.

The

accumulation of oxidative stress caused by TCR restimulation has previously been
demonstrated to be necessary for the onset of AICD. The data contained within in this
thesis reveal that accumulation of ROS escalates into the incursion of the appearance of
γH2AX foci, which are indicative of DNA damage, and activation of the DNA damage
response pathway characterized by autophosphorylation of ATM on Ser1981 and ATM
mediated phosphorylation of the tumor suppressor p53 on Ser15. Treatment with the
glutathione pro-drug N-acetyl cysteine (NAC) significantly reduced the upregulation of
γH2AX and subsequent ATM activation and cell death. Additionally, both murine Pmel-1
T cells and TIL1383I TCR transduced therapeutic human T cells exhibited less susceptibility
to the upregulation of γH2AX and onset of AICD when NAC was added to the medium
vi

during extended culture.

Both Pmel-1 T cells and TRP-1 TCR transduced murine

splenocytes cultured in NAC prior to adoptive transfer into B16F10 challenged mice
exhibited enhanced control of tumor burden and survival of recipient mice. TIL1383I TCR
transduced T cells cultured in NAC demonstrated reduced expression of the exhaustion
and senescence markers PD-1 and CD57 as well as the exhaustion associated transcription
factors EOMES and Foxo1.

Taken together, the results contained in this thesis

demonstrate the addition of NAC to the rapid expansion of therapeutic T cells bolsters
the overall fitness and anti-melanoma functionality of the cells and could potentially
improve the quality and therapeutic efficacy of adoptive T cell therapeutics infused into
patients.

vii

CHAPTER 1 – REVIEW OF LITERATURE

The Development of Adoptive Cell Transfer Therapy
In the late 1800s, William Coley, a bone surgeon from New York, observed several
cases of cancer where the patient exhibited signs of remission upon the onset of fever.
Based on these observations, Coley postulated that he could recapitulate such outcomes
by purposefully injecting sarcoma and carcinoma patients with cultures of Streptococcus
pyogenes. In 1893, he published his findings claiming such inoculations resulted in some
degree of remission up to a curative potential (1).

This seminal experiment in

manipulating the immune system towards the eradication of cancer has been widely
regarded as the origin of the cancer immunology field. However, the concept that the
immune system could invoke remediation of cancer was resisted with much skepticism
for several decades following Coley’s work (2).
During the late 1950s and early 60s, the Laboratories of Robert Baldwin & Karl
Hellström contemporaneously published several key experiments which reinvigorated
the notion that the immune system was involved in cancer defense. Baldwin induced
primary sarcomas in rats with methylcholanthrene, which were then removed via
ischemia mediated atrophy. Subsequently, Baldwin demonstrated that these rats were
resistant to a secondary tumor transplantation with syngeneic derived tumors, implying
that the primary tumor had generated an inoculation in the rat against further tumor
challenge (3). The Hellström Laboratory further established that previously tumor
challenged mice were also resistant to a secondary transplantation of autologously
1

derived tumors, confirming that the anti-cancer immunity observed in these experiments
was not a result of any unappreciated immunogenicity from donor derived tumors (4).
Later on in the 1960s, reports demonstrated that tumors in rats and mice could be
suppressed by the transfer of peripheral lymphocytes derived from tumor challenged
donor mice (5,6), thus establishing that anti-cancer immunity could be “adoptively
transferred” from one host to another.
Moving the field beyond controlling cancer through the use of peripheral
lymphocytes, in 1986, Steven Rosenberg and colleagues successfully isolated
lymphocytes embedded within the microenvironments of established murine sarcoma
and adenocarcinoma tumors through mechanical dissociation of the tumor alongside
elevated levels (1,000U/mL) of interleukin-2 (IL-2). Adoptive transfer of these isolated
“tumor infiltrating lymphocytes” (TILs) was able to control the tumor burden of tumor
challenged mice at a potency of “50 to 100 times” higher than peripherally-derived
“lymphokine-activated killer cells” (7). The following year, the Rosenberg Laboratory
successfully isolated human TILs from the tumor resections of metastatic melanoma
patients. Furthermore, these TILs were found to be capable of in vitro cytotoxicity against
autologous melanoma cells (8). Subsequently, pilot clinical trials were initiated to
adoptively transfer these patient autologous TILs into patients with metastatic
melanoma, as well as into patients with breast, colon, and renal cell carcinomas, which
demonstrated an overall manageable safety profile and resulted in some cases of partial
response (9,10). Most of the initial clinical trials of TIL therapy were purposed to treat
metastatic melanoma where it was collectively observed that approximately one-third of
2

patients achieved an objective response when TILs were administered alongside highdose IL-2 therapy (11), demonstrating the adoptive transfer of TILs to be a feasible and
potentially efficacious treatment option.
Since these pilot trials, one of the key advancements in the efficacy of TIL based
adoptive cell transfer (ACT) therapy has been the ability to preemptively condition the
patient with a non-myeloablative lymphodepleting regimen prior to cell infusion, typically
with the chemotherapeutic agents cyclophosphamide and fludarabine (12). There are
multiple mechanisms by which lymphodepletion is thought to enhance ACT. As early as
1980, it was postulated that lymphodepletion thwarted host endogenous suppressor cells
from restricting the efficacy of transferred effector T cells (13). Indeed, such suppressor
cells are an impediment for ACT. In mice, Mac-1+/Gr-1+ myeloid derived suppressor cells
have been shown to directly cause cell-death in effector CD8+ T cells (14), and in humans,
peripheral derived myeloid cells can suppress T cell proliferation (15). Additionally, the
level of host endogenous CD4+FoxP3+ T regulatory cells (Tregs) inversely correlates with
the therapeutic outcome of ACT (16). Lymphodepletion prior to adoptive transfer has
also been shown to make available homeostatic cytokines such as IL-7 and IL-15 both in
mice and in humans (17,18). Lastly, lymphodepletion is thought to aid in activating the
innate and antigen presenting compartments of the immune system. Lymphodepletion
regimens likely cause some tumor cytotoxicity releasing tumor antigens. Moreover, in
experimental mouse models, lymphodepletion via total body irradiation (TBI) has been
shown to modulate gut microbiota to release LPS, subsequently enhancing dendritic cell
activation (19). Attempts have also been made to intensify host lymphodepletion with
3

the addition of TBI to the cyclophosphamide and fludarabine regimen. An initial smallscale, non-randomized clinical trial demonstrated a complete response rate of 40% for
those receiving the highest dosage of TBI (12 Gy) (20) with all but one of those patients
maintaining the complete response beyond 5 years (21).

However, a subsequent

randomized clinical trial did not find any significant survival benefit with the addition of
TBI to cyclophosphamide and fludarabine (22).
Beyond melanoma, TILs have been detected, and are good prognostic indicator,
in renal cell carcinoma (23), head and neck squamous cell carcinoma (24,25),
hepatocellular carcinoma (26), as well as in breast (27,28), gallbladder (29), bladder
(30,31), ovarian (32–34), esophageal (35,36), colorectal (37–42), prostate (43,44), nonsmall cell lung (45,46), pancreatic (47), and cervical (48,49) cancers. In the clinic, TILs have
produced positive clinical outcomes in viral associated cancers such as EBV positive
nasopharyngeal carcinoma (50–52) and have demonstrated partial and complete
responses in HPV positive cervical cancer (53). Additionally, TIL based ACT has been
shown to mediate partial responses in glioma (54), and significantly enhance the 3 year
survival in clinical trials for non-small cell lung cancer (55) and ovarian cancer (56).

Adoptive Transfer with TCR Transduced T cells
The use of TILs for ACT is limited by the ability of a patient surgical resection to
yield TILs suitable for infusion with only approximately 45% of metastatic melanoma
patients being appropriate candidates for the therapy (20). Moreover, the repertoire of
antigen specificities, and affinities thereof, is limited to the inventory of TIL clonotypes
4

present within the harvested tumor. As an alternative approach, the T cell receptor (TCR)
genes from tumor reactive TILs have been cloned and then transduced onto autologous
peripheral T cells (57). Most TCRs are composed of an α-chain/Β-chain heterodimer (with
a minority of TCRs expressing γδ chains) (58). Each unique TCR recognizes a specific
peptide antigen fragment presented on a major histocompatibility complex (MHC)
molecule. There are two main classes of MHC molecules: MHC-I on the surface of virtually
all nucleated cells, and MHC-II which is generally restrained to antigen presenting cells.
MHC-I presents antigen to CD8+ T cells while MHC-II presents to CD4+ T cells. As MHC
molecules are polymorphic, differing in the specific structural conformation of the groove
binding the peptide, TCR recognition of a peptide is “MHC restricted” to the particular
genetic variant of MHC presenting the peptide (59,60). In the context of melanoma,
several TCRs specific for melanocyte differentiation antigens such as Melan-A (MART)
(57,61–63), glycoprotein 100 (gp100) (64–66), and tyrosinase (67–70) have been cloned
for transduction onto autologous T cells.
These melanocyte differentiation antigens are overexpressed on melanoma
tumors, yet are still expressed in healthy melanocytes, which can in some instances
potentiate the occurrence of autoimmunity (62).

Alternatively, TCRs have been

engineered on T cells to recognize another class of antigen: the cancer-testis (CT) antigen.
CT antigens are a class of antigen of which expression is generally exclusive to male
germline cells, normally absent from healthy adult somatic tissues, but can reappear
during oncogenesis in various cancers (71). T cells transduced with a TCR directed against
the CT antigen NY-ESO-1 and MAGE-3 were able to mount in vitro cytolytic lysis against
5

relevant antigen expressing melanoma and nonmelanoma cancers including
neuroblastoma and non-small cell lung cancer, respectively (72,73). In the clinic, the NYESO-1 TCR has mediated objective responses against synovial cell sarcoma and melanoma
(74) and has also shown clinical activity against multiple myeloma (75). Currently, the use
of the NY-ESO-1 TCR is being expanded in clinical trials for breast, lung, esophageal,
ovarian, and bladder cancers as well as neuroblastoma (76). Additionally, the MAGE-3
TCR elicited cancer regression in the clinic against melanoma and synovial sarcoma,
though further use was discontinued due to the occurrence of fatal on-target off-tumor
toxicity (77).
Achieving the appropriate TCR affinity for a target antigen remains an open
avenue of optimization. The affinities of TCRs cloned from TILs targeting tumor associated
antigens, which are co-expressed on non-malignant cells, are likely constrained by central
tolerance (78,79). Moreover, limitation in antigen expression caused by tumor immune
evasion maneuvers, such as the downregulation of MHC molecules (80), likely
necessitates an appropriately high enough TCR affinity for optimal TCR-pMHC binding
essential for T cell activation (81). In the original pilot trial of TCR engineered cells for ACT
in 2006, 15 melanoma patients were treated with autologous peripheral lymphocytes
transduced with a TCR specific for MART-1. Compared to TIL based therapy, the response
was relatively low with only two (13%) of the patients exhibiting an objective response to
the treatment (82). A subsequent trial was reported in Johnson, et al. where transferred
T cells were transduced with a TCR of a higher affinity for MART-1 which resulted in an
elevation in the objective response rate to approximately 30% (62).
6

This increase in efficacy highlights the importance of generating TCRs with an
appropriately high affinity for the target antigen. However, several preclinical studies
have demonstrated that there is likely an upper-limit to the increase in anti-tumor efficacy
with enhanced TCR affinity. Dougan, et al. generated two different strains of transnuclear
mice with T cells expressing either a high or low affinity TCR for the melanoma antigen
tyrosinase-related protein 1 (TRP-1) using somatic cell nuclear transfer technology. The
difference in affinity for TRP-1 between the two TCRs was nearly 100-fold, yet when these
T cells were activated ex vivo and transferred into B16 challenged mice, both strains
conferred a survival benefit and control of tumor burden that was indistinguishable in
magnitude between the low and high affinity TCR (83). Other investigators have used a
panel of increasing TCR affinities for the same antigen to more precisely determine the
relationship between affinity and in vivo anti-tumor efficacy. Zhong, et al. used a panel
of TCRs with increasing affinity towards gp100 and found that increasing the affinity
towards gp100 did enhance anti-tumor efficacy, but this enhancement was plateaued at
a TCR affinity of 10µM (84). A similar plateau was seen with a panel of increasing TCR
affinities for NY-ESO-1 (85). Another study generated TCR affinities for NY-ESO-1 beyond
the physiological range, which resulted in diminished T cell functionality (86). One
potential explanation for this phenomenon is the increased expression of SHP-1, an
inhibitor of TCR signaling (87), alongside increasing TCR affinity (88), implicating an
intrinsic negative feedback mechanism against such supraphysiologic TCR stimulation.
Moreover, it has been reported that T cells with higher affinity TCRs are more susceptible
to tolerization within the tumor microenvironment (89). Enhancements in affinity also
7

increase the likelihood of autoimmune complications with therapy, particularly with TCRs
that target antigens co-expressed on non-malignant tissues.

As such, the T cells

transduced with the higher affinity anti-MART1 TCR also targeted MART-1 expressing
melanocytes in the skin, eyes, and ears resulting in the development of vitiligo and
transient onsets of uveitis and hearing loss (62). In the context of tumor associated
antigens shared between healthy and tumor cells, lowering the antigen affinity allows for
preferential targeting of tumor cells as they significantly overexpress the antigen
compared to normal healthy tissues (90,91). Additionally, more severe on-target offtumor side effects have been observed with the use of TCR transduced T cells. A pilot
clinical trial utilizing a TCR recognizing the CT carcinoembryonic antigen to treat
gastrointestinal cancers had to be halted because all of the treated patients developed
severe inflammatory colitis (92). More drastically, in the clinical trial utilizing the TCR
directed against the CT antigen MAGE-A3, two patients died as a result of treatment
induced neurotoxicity, as it was later determined that MAGE-A12, also recognized by the
TCR, was previously unappreciated to be expressed in the brain (77). Another clinical trial
with MAGE-A3 TCR transduced cells resulted in fatal cardiac toxicity potentially caused by
a cross-reactive epitope on the striated muscle protein Titin (93). Altogether, the
technology to engineer autologous T cells with a tumor-antigen specific TCR represents a
feasible treatment option for cancer. However, there remains a disparity in the treatment
efficacy compared to TIL therapy, and further enhancements are needed to fine-tune
appropriate antigen specificities and affinities that are both efficacious and safe.

8

One approach to the generation of appropriate TCRs for transduction is to use
whole exome sequencing to identify nonsynonymous mutations between healthy and
malignant tissues which are subsequently screened for TIL recognition (94,95). The
rationale for this approach builds off of the success of anti-PD1 therapy, which reports
have suggested is mediated by T cells recognizing mutated antigens (96). Additionally,
some reports have associated mutation specific TILs with positive outcomes in ACT
(97,98), and T cells transduced with a KRAS-mutant specific TCR have shown efficacy in a
preclinical pancreatic cancer model (99). Furthermore, this approach could potentially
expedite the application of ACT immunotherapy towards cancers with lower mutation
rates than melanoma (100), such as the clinically observed regression in a bile duct cancer
patient treated with an ERBB2IP-mutation specific TIL (101).

Chimeric Antigen Receptor Engineered T Cells
An alternative approach to the transduction of T cells with a conventional αβ TCR
is to transduce cells with a Chimeric Antigen Receptor (or CAR). CAR T cells, originally
described by Gross and colleagues in 1989, are a fusion protein combining the antigen
binding domain of an antibody with the intracellular signaling domain of a T cell (102).
The use of an antibody antigen binding domain allows the CAR T cell to be MHC
independent as well as able to bind to non-protein epitopes. Original CARs simply
contained the CD3ζ domain of the TCR signaling complex and were lackluster in their
clinical efficacy due to poor persistence (103,104).

9

Subsequently, co-stimulatory

domains, such as CD28 or 4-1BB have been added, which have markedly improved both
the persistence and therapeutic efficacy of CAR T cells (105,106).
CAR T cells have been primarily beneficial in the treatment of hematological
cancers targeting the B-cell antigen CD19 where they have demonstrated an over 50%
response rate in chronic B-cell leukemia (107) and complete response rates upwards of
90% in patients with acute lymphoblastic leukemia (108). Though currently the efficient
use of CAR T cells has been restrained to hematological cancers, many investigators are
looking at ways to target solid tumors with CAR engineered T cells. To that end, many
CARs have been developed targeting relevant antigens, and have shown preclinical
efficacy, in breast cancer (109–111), gastrointestinal cancers (112–114), glioblastoma
(115–119), lung cancer (120,121), neuroblastoma (122,123), pancreatic cancer (124–
126), osteosarcoma (127,128), ovarian cancer (103,129,130), cervical cancer (131),
prostate cancer (132–135), renal cell carcinoma (136,137), and hepatocellular carcinoma
(138,139). Though success in the clinic has remained more elusive, several small-scale
clinical trials have demonstrated partial responses in patients with non-small cell lung
cancer using anti-EGFR CAR T cells (120) and in prostate cancer with anti-PSMA CAR T cells
(133). Additionally, there have been reports of complete responses in glioblastoma with
an anti-IL13Rα2 CAR T cell (140) and in neuroblastoma with an anti-GD2 CAR T cell (122).
However, other pilot clinical trials utilizing T cells transduced with CARs directed against
solid tumors have demonstrated severe (92,137,141) and even fatal (142) toxic events.
Unfortunately this has slowed down the clinical development of CAR engineered T cells
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against solid tumors towards stringent dose-escalation trials, which have made it difficult
to discern clinical efficacy (143).
To limit toxicities, investigators are currently working to engineer CARs with
additional safety modifications. These approaches include incorporation of suicide genes
such as Herpes simplex virus thymidine kinase or inducible caspase 9 which can be
induced by either treatment with ganciclovir or the dimerization agent AP1903,
respectively, to purposely eliminate transferred cells in order to modulate any escalation
of on-target off-tumor toxicities (144,145). Alternatively, the CAR can be engineered to
co-express a cell surface epitope that can be recognized by an already approved
monoclonal antibody therapy such as rituximab or cetuximab, resulting in CAR T cell
deletion (146,147). Conversely, the CARs may be inducible themselves, being only
activated when given an exogenous peptide or small-molecule drug (148–150).
Furthermore, the specificity of CARs can be enhanced by creating bi-specific “tandem”
CARs whereby two antigens must be present on a cell to trigger CAR effector function
(151,152).

Correlatives of Success with Adoptive Transfer Therapy
Unfortunately, reports of clinical success with adoptive cell transfer therapy must
be balanced by the fact that the majority of patients do not generate a durable complete
response. Understanding key correlatives of success and failure between responding and
non-responding patients is therefore important for bridging this gap in therapeutic
efficacy. Certain host factors can influence therapeutic success such as the individual
11

tumor’s ability to evade immune detection via downregulation of MHC molecules (80).
Similarly, development of resistance to CART19 therapy can be driven by either the
mutation or loss of expression of CD19 (153,154). However, overall, there has not been
a correlation between bulk of disease and/or the nature of metastasis with the
therapeutic success of ACT (155).
Rather, the quality of the T cell used for infusion seems to be of paramount
importance to therapeutic success. Both the age and differentiation status of the cell
have been shown to correlate with clinical outcomes.

In general, younger, less-

differentiated cells consistently demonstrate superiority in therapeutic efficacy. A mouse
study, which adoptively transferred cells stratified at different effector stages (naïve, early
effector, immediate effector, effector) demonstrated an inverse correlation with
differentiation status and ability to control tumor (156). This observation has also been
extended to murine TCR transduced naïve cells being more anti-tumor efficacious than
more differentiated memory cells (157). In fact, it has recently been shown that even the
presence of memory cells during culture expansion can impair the anti-tumor efficacy of
naïve cells (158). As such, there have been several attempts in the clinic to use shorter
cultured “young” TILs, of which pilot studies have shown promising improvement in
efficacy (159,160).
Consistently, telomeres, which degrade during cell-replication, and are therefore
indicative of a cell’s replication history, have also been shown to correlate with
therapeutic outcomes. Patients receiving TILs with longer telomeres (i.e. have been
through less replications) are significantly more likely to respond to therapy than patients
12

receiving TILs with shorter telomeres (18,161,162).

Moreover, expression of

costimulatory molecules also correlates with improved outcomes. Higher expression
levels of CD27 (163), CD28 (162), and 4-1BB (164) associate with enhanced anti-tumor
efficacy in preclinical and clinical studies. Additionally, as older, more differentiated cells
are susceptible to senescence, and also lack the durability and proliferative capacity of
younger, less differentiated cells (165), lack of cell persistence after transfer has also been
shown to correlate with poor patient outcomes (166).
The quantity of cells infused is also important as studies have shown that
responding patients receive a significantly higher number of cells than comparable nonresponding patients. (159,167). In order to achieve enough cells for treatment, both TILs
and TCR transduced cells undergo a Rapid Expansion Protocol (REP) whereby cells are
typically stimulated polyclonally by anti-CD3 cross-linked on irradiated feeder cells with
continued supplementation of IL-2 (168). However, counterproductively, cells that have
undergone a REP have decreased expression of CD28 and CD27 (156,169). Additionally,
post-REP cells have decreased telomere lengths compared to pre-REP cells (170). They
are also more susceptible to deletion by activation-induced cell death (171). Thus,
counter-acting the terminal differentiation promoting influence of the REP is likely a
critical therapeutic intervention point to improve the quality and therapeutic efficacy of
expanded anti-melanoma T cells.

13

Melanoma
The cancer of melanoma has been in the forefront of progress in cancer
immunotherapy as it is notably one of the most immunogenic of cancers, likely due to its
high mutation rate producing neoantigens (100).

Several key observations have

supported melanoma as a vanguard for the immunotherapy field. There are extremely
rare cases where metastatic melanoma has spontaneously regressed without an
attributable therapeutic cause (172–174). Incidences of melanoma are higher, and the
prognosis is poorer, amongst immunocompromised individuals such as HIV patients or
organ transplant recipients (175–177). Conversely, onset of the autoimmune condition
vitiligo correlates with better outcomes for metastatic disease (178,179). The success
gained by IL-2 therapy demonstrates that actively stimulating the immune system can
modulate cancer regression.

Moreover, the discovery of lymphocytes which have

penetrated the tumor microenvironment evidences the direct targeting of melanoma
cancer cells by cytotoxic T cells (8,180,181).
While the incidence rates of most cancers are on the decline in the United States,
melanoma is one of a few cancers increasing in both occurrence and mortality in the US,
and is one of the fastest growing cancers worldwide (182). Over the past two decades,
the rate of people diagnosed with melanoma has increased 3.1% per year with an
estimated 17-fold and 9-fold increase in incidence rates for men and women,
respectively, within the US since the 1960s (183,184). Concurrently, since the 1960s, the
mortality rate due to metastatic melanoma has been progressively increasing by 2% each
year (183). In 2014, there were an estimated 76,100 new cases of melanoma in the US
14

with 1,350 of those cases occurring in South Carolina. Moreover, in 2014, it is estimated
that there were 9,710 deaths attributed to melanoma (185). At this current incidence
rate, it is now projected in the US, that men have a 1-in-33 chance and women have a 1in-52 chance of developing melanoma within their lifetime (186).
The overall prognosis for melanoma is fairly encouraging with 5 and 10 year
survival rates of 92% and 89%, respectively (187). However, these data are heavily
weighted towards approximately 84% of melanomas being diagnosed at an early stage of
development (187). Once the stage of initial detection is considered, the prognosis of
melanoma is highly dichotomous based on when it is initially diagnosed. Melanomas
detected while they are ≤1 mm in thickness, and have not metastasized, have a very high
cure rate via surgical resection with 5 year and 10 year survival rates of 97% and 93%,
respectively (188). However, once the primary melanoma tumor has grown to a depth
of 4 mm, even before the detection of metastatic nodes, the 10 year survival rate of Stage
IIC cancer quickly diminishes to 39% (188). For nearly one-in-five melanoma patients
(20.5%), the cancer will metastasize into Stage IV disease (188) where the prognosis is
exceedingly grim with a 5 year survival rate of only 15.2% (189).

Oncogenesis of Melanoma
Melanoma is a cancer originating from the melanocyte cell. The overwhelming
majority of melanoma cases are cutaneous (~91.2%) with the additional rarer forms
occurring as ocular and mucous membrane melanomas (190). Melanocytes, the pigment
producing cells of skin and hair follicles, continually regenerate throughout an individual’s
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lifetime potentially making them more malleable to carcinogenic transformation (191).
Melanomas typically arise from a cluster of melanocytes known as a nevus (or commonly
referred to as a “mole”). The overwhelming majority of nevi are benign and do not
progress to melanoma. However, genetic damage causes a rare minority of nevi to
become dysplastic and progress into radial growth in the epidermis (192). The majority of
melanomas present with mutations in either the N-RAS or BRAF cell proliferation
pathways (192,193). The most prevalent mutation is in BRAF, estimated to occur in
upwards of 66% of malignant melanoma cases (194) commonly presenting as a ValineGlutamic Acid substitution at residue 600 (BRAFV600E). This substitution causes an
approximately 700-fold increase in B-raf kinase activity, resulting in constitutive activation
of the Ras-Raf-MEK-ERK pathway promoting inappropriate cell proliferation (195,196).
In melanoma, as in most cancers, enhanced proliferation is generally coupled with
loss of cell cycle control mechanisms. Typically, melanomas have been reported to thwart
proper cell cycle control by either inactivating the CDKN2A or PTEN genes. Loss of
function for the CDKN2A gene leads to a deficiency in the cell cycle regulator p16INK4a
loosening restrictions on cell cycle progression (197). Similarly, mutations inactivating
PTEN allow levels of PIP3 to increase permitting an unregulated increase of activated Akt,
promoting cell survival and proliferation (198).
After sufficient radial progression, melanomas begin to grow vertically and burrow
through dermal layers. Loss of functional PTEN leads to a switch from E-cadherin to Ncadherin expression on the surface of melanoma cells (199).

Loss of E-cadherin

expression, which restrains melanoma proliferation via cell-to-cell contact with adjacent
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keratinocytes, allows more migratory freedom for the expanding tumor mass (200–202).
Additionally, as melanomas become more aggressive, they begin to express the αvβ3
integrin which secrets the active form of metalloproteinase MMP-2. MMP-2 is an enzyme
that actively degrades collagen in the basement membrane eventually creating a path to
metastasis for the evolving tumor (203).

Melanoma Treatment Options
For Stage I melanomas, the cancer can generally be cured via surgery, with a 5
year survival rate of approximately 98% (187). Unfortunately, once melanoma has
metastasized into a Stage III–IV cancer, treatment options are more limited in their
efficacy.

Chemotherapy
In the 1970s, the chemotherapeutic agent Dacarbazine emerged as one of the first
approved therapeutic options for late stage melanoma and has represented the mainline
standard-of-care since then. Preclinical studies demonstrated that Dacarbazine exhibited
an in vivo antitumor effect against the leukemic cell line L1210 (204) as well as murine
sarcoma, adenocarcinoma, and melanoma tumors (205,206).
Initial clinical trials administered Dacarbazine as an oral agent, which
demonstrated incomplete and inconsistent absorption (207). Dacarbazine itself does not
have anti-neoplastic activity. It must be first metabolized to the reactive byproduct 5-[3methyl-triazen-1-yl]-imidazole-4-carboxamide (MTIC) in the liver via the cytochrome
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P450 (208). The drug was henceforth administered intravenously. Phase III trials
demonstrated a partial response rate of 14.8% and a complete response rate of 4.1%
(209). However, these responses were not durable as 64.2% of complete responders
relapsed within 37 weeks of treatment, and overall, only 1.4% of the original patient
cohort was disease free at 74 months (209).
In the early 1990s, Temozolomide emerged in phase I trials as oral alternative to
Dacarbazine (210,211).

The drug demonstrates a near 100% bioavailability when

administered orally and is capable of spontaneous conversion to the active agent MTIC
without need of hepatic metabolism (210,212). While Temozolomide is more convenient
to administer, it has unfortunately not demonstrated any significant improvement in
therapeutic efficacy compared to Dacarbazine (213) with the exception that it can
potentially cross the blood-brain barrier in the treatment of central nervous system
metastases (212,214,215).
Dacarbazine and Temozolomide are generally regarded to have a manageable side
effect profile (216). However, these agents have only produced a median overall survival
of 5.6-7.8 months (217) and are likely, at best, only a palliative care option. Since the
development of Dacarbazine, there have been many attempts and trials to combine
various chemotherapeutic agents, including the often investigated “Dartmouth Regimen”
of Dacarbazine alongside cisplatin and vinblastine. However, none of these have offered
a serious advantage to life extension compared to Dacarbazine alone (218). Altogether,
chemotherapeutics have not demonstrated any convincing potential as a curative agent
for metastatic melanoma (219).
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High Dose Interleukin-2
Since Dacarbazine, no drug or agent demonstrated any significant improvement
in outcomes for metastatic melanoma patients until the FDA approval of high-dose
Interleukin-2 (IL-2) in 1998 (220,221). IL-2 was originally discovered as a “T cell Growth
Factor” in 1976 capable of stimulating in vitro lymphocyte proliferation (222). Thus,
treatment with IL-2 exhibited the potential of manipulating the immune system towards
tumor eradication (223). Treatment with high-dose IL-2 yields an objective response rate
of approximately 16% with a subset of complete responders of around 6% (224).
Moreover, nearly 70% of these complete responders never relapse (219), which made IL2 a breakthrough in the durable management of metastatic melanoma. However, highdose IL-2 treatment results in a complex side effect profile often requiring hospitalization
for treatment. Consequently, current analysis reveals, at best, only 10% of eligible
patients participate in this potentially curative treatment (219).

Interferon-α
The in vivo administration of interferon-α (IFN-α) has been characterized to
bolster the immune system towards an anti-tumor response through several
mechanisms. IFN-α promotes the maturation, and enhances the antigen presenting and
co-stimulatory functionality, of dendritic cells (225,226). Additionally, IFN-α increases the
Th1 immune response by increasing IFN-γ secretion by T cells (227), which is critical for
the anti-tumor priming of T cells as well as promoting the upregulation of MHC expression
(228) and oncogene induced senescence in melanoma cells (229). Ultimately, in vivo
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tumor regression by IFN-α involves increased infiltration of dendritic cells and T cells into
the tumor microenvironment (230).
Administration of IFN-α has not been very effectual for the eradication of
unresected melanoma. Clinical trials which have attempted to combine IFN-α with
various chemotherapeutic regimens were not able to show any increase in overall survival
benefit from the addition of IFN-α (231–234). However, the use of high-dose IFN-α
(specifically IFN-α2b) as an adjuvant therapy, to prevent relapse following surgical
resection, has been shown to improve both the progression free survival and overall
survival in patients with high-risk melanoma (235–238). Therefore, use of IFN-α2b in the
adjuvant setting was approved by the FDA in 1995. The pegylated form of IFN-α2b, which
results in a nearly 10-fold increase in the half-life compared to unmodified IFN-α2b (239),
has also been developed and has been approved by the FDA for adjuvant treatment of
melanoma.

However, it is currently unclear if the pegylation has improved the

therapeutic benefit of IFN-α2b as two phase III trials have showed no improvement in
overall survival when compared to either observation (240) or unmodified IFN-α (241).
Additionally, it should be cautioned that a phase III trial of patients with
“intermediate-risk” melanoma showed that there was no benefit from IFN-α2b adjuvant
therapy, and patients had a reduced quality of life due to nearly 58% of the treatment
group experiencing grade 3 or higher toxic side effects (242). Altogether, IFN-α is likely
beneficial as an adjuvant therapy for post-resected, high-risk melanoma patients.
Furthermore, while it has not demonstrated robust clinical efficacy in unresected disease,
there is a renewed interest to determine if it can enhance the efficacy of immune
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checkpoint blockade inhibitors. Clinical trials are currently underway to determine if
there is any additive or synergistic effect in combining IFN-α with the anti-CTLA-4 agents
Tremelimumab and Ipilimumab as well as with Pembrolizumab (anti-PD1) (243,244).

Vaccines
The immunogenic nature of melanoma has inspired many investigators to
engineer vaccines that could potentially bolster a patient’s immune system towards
tumor eradication. Unfortunately, the overwhelming majority of clinical attempts have
failed to exhibit a substantive patient response (245). The earliest vaccine attempts were
whole cell vaccines utilizing irradiated autologous tumor cells obtained from surgical
resections. Clinical trials using whole cell vaccines to treat melanoma have only been able
to report an overall response rate in the range of approximately 3.85%-12.5% (246–249).
Additionally, whole cells vaccines derived from allogenic melanoma cell lines have been
developed (Melacine®, VMCL, VMO) and tested in the clinic for post-surgical adjuvant
treatment. None of these have demonstrated an improvement in overall survival (250–
252). In fact, a phase III trial of the allogenic whole cell vaccine Canvaxin™ had to be
canceled when it was demonstrated that patients treated with Canvaxin™ had survival
rates significantly lower than placebo treated controls (253).
Dendritic cell vaccines have also been used in an attempt to enhance the
presentation of tumor antigens to the immune system by pulsing dendritic cells with
melanoma peptides prior to patient infusion. While this approach has demonstrated
encouraging results in increasing the overall survival rates in a post-surgical adjuvant
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setting (254), in the treatment of unresected disease, phase I/II trials have only been able
to demonstrate a handful of regression events (255–257). Moreover, a randomized phase
III trial of dendritic cell vaccine treatment did not demonstrate an increase in efficacy
when compared to Dacarbazine chemotherapy (258).
Other vaccines approaches include ganglioside vaccines that attempt to exploit
the high levels of immunogenic gangliosides on the surface of melanoma cells (259).
Currently, these have only been investigated within the context of post-surgical adjuvant
therapy and have not shown any increase in clinical benefit in comparison to either
observation (260) or INF-α2b therapy (236). DNA vaccines directly inject the genetic code
for melanoma antigens either through the use of plasmid DNA or recombinant viral
vectors. Clinical trials using DNA vaccines have either reported minimal (3.33%) to no
clinical response (261,262) or were unable to distinguish a definitive benefit in contrast
to IL-2 co-treatment (263,264).

However, another viral vaccination approach, the

oncolytic virus T-VEC (Talimogene Laherparepvec, formerly OncoVexGM-CSF) has shown
clinical benefit. T-VEC is a herpes simplex virus type 1 (HSV-1) which has been modified
for enhanced targeting of tumors for replication and lysis (265) as well as to secrete
granulocyte-macrophage colony-stimulating factor (GM-CSF) (266). In a phase III clinical
trial, T-VEC had a higher overall response rate compared to GM-CSF control (26.4% vs
5.7%) as well as an improvement in median overall survival (23.3 vs 18.9 months, p=0.51)
(267). As such, in 2015, T-VEC (trademarked as IMLYGIC) became the first oncolytic viral
therapy to be approved by the FDA (268).
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By far, peptide vaccines, which directly inject the peptides of melanoma antigens,
have been the most extensively tested in trying to generate an immune response against
unresected melanoma. Historically, trials experimenting with various antigen peptides
(MART-1, TRP-1, TRP-2, gp100, Tyrosinase, MAGE-12, NY-ESO-1) have demonstrated a
limited overall response rate of approximately 2.9% (245). One outlier to this trend is a
phase III trial reporting a higher overall clinical response rate with gp100 peptide vaccine
and high-dose IL-2 in comparison to IL-2 therapy alone (16% vs 6%) (269). However, it
should be noted that the IL-2 alone treatment group grossly underperformed the
historically observed response rate for high dose IL-2 therapy (~16%) (219,224). Other
trials have demonstrated that adding gp100 peptide vaccine did not enhance the benefit
of high dose IL-2 (270).

Furthermore, peptide vaccine treatments have not been

improved by the addition of INF-α2b or GM-CSF (271), nor have peptide vaccines
demonstrated a benefit in a post-surgical adjuvant setting (272). Altogether, despite
much effort to use vaccines towards the eradication of unrested melanoma, clinical
success towards that goal has been minimal and sporadic (273). Besides T-VEC, the only
other cancer vaccine to be approved by the FDA is Sipuleucel-T for castration-resistant
prostate cancer, which has only been able to improve median survival by approximately
4.1 months (274,275).

B-raf and MEK Targeted Inhibitors
In 2011, the FDA approved Vemurafenib, which specifically targets and inhibits the
BRAFV600E mutation (276), as it demonstrated a significantly higher overall response rate
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compared to Dacarbazine (48% vs 5%) in a phase III clinical trial, with interim analysis
compelling a recommended crossover from Dacarbazine to Vemurafenib (217).
Unfortunately, these responses have not demonstrated durability as, in most cases, the
residual tumor burden develops resistance to the treatment (277) resulting in a
progression free survival of only approximately 6.2 months (278). Additionally, by
definition, this treatment option excludes nearly half of all melanoma patients that do not
have BRAFV600E mutant tumors (192), and of those that do, the heterogeneity of a
patient’s melanoma burden may likely contain BRAF-WildType (BRAFWT) cells intermixed
with mutant cells, unaffected by the treatment (279). Moreover, Vemurafenib has been
shown to counterproductively activate MAPK/ERK pathways in BRAFWT cells (280) making
the development of secondary malignancies, such as the noticeable onset of squamouscell carcinoma, a continuing point of concern (217,281).
Alternatively, inhibitors targeting downstream MEK, such as Trametinib, have
been developed (282). Trametinib has shown a modest benefit in overall survival when
compared to chemotherapy. However, MEK inhibition did not demonstrate a significant
improvement in efficacy when compared to previous trials with Vemurafenib, excluding
the caveat that treatment does not exclude patients with BRAFWT tumors (283).
Based on the rationale that the principle resistance mechanism of melanoma to
BRAF targeted therapy is reactivation of the MEK/MAPK pathway (284,285), investigators
have recently been investigating the combination of BRAF and MEK inhibition. Initial
clinical trials demonstrate a promising increase in efficacy compared to single agent
treatment with the FDA approval of combining Vemurafenib with the MEK inhibitor
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Cobimetinib (286). This was based on a phase III clinical trial which showed an overall
response rate of 68% (versus 45% in the Vemurafenib alone group) with a median
progression-free survival of 9.9 months (versus 6.2 months for Vemurafenib) (278).

CTLA-4 and PD-1 Immune Checkpoint Inhibitors
In 2011, Ipilimumab, an antibody targeting the T cell inhibitory receptor CTLA-4,
was approved for the treatment of late-stage melanoma. CTLA-4 negatively regulates T
cell activation and proliferation (287), and impediment of CTLA-4 via a blocking antibody
has demonstrated pre-clinical in vivo improvement in tumor control as early as 1996
(288). Ipilimumab was developed by Keler and colleagues in 2003 as a human monoclonal
antibody (MDX-010) against CTLA-4 (289). MDX-010 was later acquired by Bristol Myers
Squibb and Madarex and subsequently termed Ipilimumab (with the trade name
“Yervoy”). A phase III trial comparing Ipilimumab to patients receiving a gp100 peptide
vaccine demonstrated a significant improvement in overall survival (10.1 months versus
6.4) with 23.5% of Ipilimumab treated patients being alive at 24 months post-treatment
compared to 13.7% in the vaccine treated group (290). However, the side effects of
Ipilimumab treatment were fairly severe as 60% of treated patients developed an
immune-related adverse event, with 10-15% being a grade 3 or 4 event, and 2.1%
resulting in a drug related fatality (290). Retrospective analysis of initial phase II/III trials
report a 22% three-year survival rate for Ipilimumab treated patients, which was
improved slightly (26%) for treatment-naïve patients (291).
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Beyond melanoma,

treatment with Ipilimumab has also shown positive clinical benefit in renal cell carcinoma
(292), prostate cancer (293), and ovarian cancer (294).
More recently, the targeting of another T cell inhibitor receptor, PD-1, has
demonstrated even more encouraging results than Ipilimumab. In 2015, the anti-PD-1
antibody, Pembrolizumab, demonstrated a significant enhancement in progression free
survival compared to Ipilimumab (47.3% versus 26.5%) (295). In 2016, another clinical
trial demonstrated an overall objective response rate of 33% (296). These results led
Pembrolizumab to be approved the same year as a first-line treatment option for BRAFWT
melanomas. Additionally, another anti-PD-1 antibody, Nivolumab, has also demonstrated
objective responses in the clinic for melanoma with a 30.8% increase in overall one-year
survival and a 26.1% increase in the objective response in melanoma patients (BRAFWT)
compared to Dacarbazine (297), and has also shown clinical benefit for non-small-cell lung
cancer, prostate cancer, and renal cell cancer (297–304). Nivolumab has also been shown
to be a successful secondary treatment when Ipilimumab has failed (298). Moreover, in
addition to being more effective than Ipilimumab therapy, both Pembrolizumab and
Nivolumab were generally well tolerated without demonstrating the safety concerns
associated with Ipilimumab (305).
Being that the inhibitory receptors CTLA-4 and PD-1 are relevant at different
stages in the cytotoxic T cell response, with CTLA-4 interfering in initial activation and PD1 being engaged by PD-L1 in the tumor microenvironment, it has been postulated that
combining anti-CTLA-4 and anti-PD1 therapies may result in an even greater therapeutic
optimization. Indeed, the combination of Nivolumab with Ipilimumab resulted in a
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significantly higher objective response rate than Ipilimumab alone (61% vs 11%) (306).
Moreover, while none of the Ipilimumab-alone cohort exhibited a complete response,
22% of those receiving the combination therapy had a complete response (306). A 2016
follow-up study of that trial and another phase III trial found that patients treated with
the combination therapy had a 10.2% higher 2-year survival rate that patients treated
with Ipilimumab alone (63.8% vs 53.6%) (307).

Additionally, in a separate study, the

combination of Nivolumab plus Ipilimumab resulted in an enhancement of progression
free survival compared to either single agent therapy (11.5 months for combination
therapy, 6.9 months for Nivolumab, 2.9 months for Ipilimumab) (308).

Emerging Combination Therapies
Several

studies

have

shown

that

BRAF

inhibitors can

produce

an

immunomodulatory effect in the context of melanoma. The BRAFV600E mutation has been
reported to interfere with MHC-1 antigen processing (309), and conversely, BRAFV600E
inhibitors have been shown to enhance antigen presentation by melanoma cells (310).
Moreover, BRAF inhibition does not appear to interfere with lymphocyte function (311)
and some studies have suggested BRAF inhibition even enhances T cell activation (312).
Consequently, BRAF inhibition also demonstrates enhanced tumor infiltration by T cells
(313). In addition to promoting T cell activation, BRAF inhibition, conversely, decreases
production of immunosuppressive factors such as IL-10, VEGF, and IL-6 by melanoma cells
(314).
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Based on these observations, the rationale has been put forth to combine
BRAFV600E inhibition with an immune checkpoint inhibitor. A pre-clinical study has shown
that the combination of BRAF inhibition and PD-1 blockade produces a more durable antitumor response than either single agent alone (315). Currently, several trials are
investigating the combination of targeted inhibitors with immune checkpoint blockade.
An initial trial was limited by toxicity (316), and other trials are ongoing though have not
been yet able to show data (317).

Immunotherapy Models for Melanoma
This thesis project has employed several models to determine how the
administration of N-acetyl cysteine can modulate the phenotype and anti-tumor
functionality of melanoma-specific T cells. As demonstration of the enhancement of in
vivo efficacy was the overarching intent of these studies, two models were used to treat
C57BL/6 wild-type mice challenged with B16-F10 murine melanoma tumors. One model,
utilized Pmel-1 transgenic T cells to represent therapeutic T cells with native TCRs, while
the other model transduced peripheral T cells with a TRP-1 specific TCR to demonstrate
experimental modulation of engineered T cells. Additionally, to determine the effect of
N-acetyl cysteine on human therapeutic cells, patient autologous T cells transduced with
the TIL1383I TCR were obtained from patients undergoing a melanoma clinical trial
alongside samples obtained from healthy donors.
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The Pmel-1 Model
The repertoire of antigens available from any tumor is highly composed of nonmutated, self-antigens, which present a significantly high hurdle of poor immunogenicity
that the immune system must overcome for an effective anti-tumor response. Therefore,
effective in vivo models must adequately represent this handicap for optimal translational
relevance, which is lacking from models which utilize foreign antigens as targets.
The murine B16 melanoma cell line has been regarded as an exceptionally “poorly
immunogenic” tumor cell as it expresses no surface MHC-II and very little MHC-I
(318,319). In 1997, one of the murine self-antigens expressed by B16 melanoma cells,
gp100 (or PMEL17), was cloned (320). Gp100 is indeed a self-antigen as it is involved in
the maturation of melanosomes, the pigment producing organelle in healthy melanocytes
(321). The following year, Willem Overwijk and colleagues immunized mice with human
gp100 (as murine gp100 did not elicit a proper immune response) and generated T cell
“clone 9.” This clonotype faithfully recognized and killed B16 melanomas cells implanted
into mice in vivo (322). In 2003, the same research group, using the RNA isolated from
“clone 9” generated transgenic mice expressed this MHC-1 restricted gp100 specific TCR
named the Pmel-1 mouse (323). Greater than 95% of the CD8+ cells from generated
transgenic mice expressed Vβ13, the specific TCR-β chain inserted into the transgene.
However, despite the overwhelming presence of anti-gp100 specific T cells, these mice
were just as vulnerable to a B16 melanoma challenge as wild-type C57BL/6 mice.
However, isolated splenocytes from these Pmel-1 mice adoptively transferred alongside
gp100 peptide stimulation and IL-2 effectively controlled the tumors in B16 challenged
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C57BL/6 wild type mice. Thus, the Pmel-1 transgenic mouse does provide T cells with
TCRs which recognize murine gp100 on B16 melanoma cells and mounts a cytolytic
response in vivo which can serve as a platform to model the adoptive transfer of T cells
with native bearing antigen specific TCRs. However, these cells must be activated via
stimulation with the altered peptide ligand of the human homologue of gp100 for
optimum anti-tumor efficacy (322), which does not completely parallel adoptive transfer
protocols in the clinic.

Transduced TRP-1 TCR Model
To model the use of TCR engineered cells in the clinic, this thesis project utilized
an institutionally available cellular transduction core to transduce wild type C57BL/6
mouse splenocytes with a TCR specific for the melanoma associated antigen tyrosinaserelated protein-1 (TRP-1) (324). TRP-1 is another self/tumor antigen which functions in
healthy melanocytes to stabilize tyrosinase activity and likely protects against oxidative
stress in the process of melanogenesis (325). TRP-1 specific T cells, derived either from a
native-TCR expressing transgenic mouse or from the transduction of a TRP-1 specific TCR,
do mediate control of B16 tumors in vivo, and in contrast to the Pmel-1 model, do not
require peptide stimulation prior to transfer to elicit anti-tumor functionality (324,326).

Human TIL1383I TCR Transduced Cells
For the most expeditious determination of the clinical relevance for the findings
in this thesis project, T cells transduced with the therapeutic TIL1383I TCR currently being
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generated as part of a phase I clinical trial (NCT01586403) were obtained for experimental
use. The generation of these cells began when TILs from “patient 1383” (327) were
cultured and tested for reactivity, demonstrating that culture “TIL 1383 I” was specifically
reactive against HLA-A2 expressing melanoma cells yet was not reactive against non-HLAA2 and/or non-melanoma tumor cells (328). Subsequently, the cognate antigen targeted
by this TIL culture was determined to be the 368-376 peptide epitope of tyrosinase
(hTyr368-376) of either the 370D genetically encoded or the 370N post-translationally
modified variation (328,329).
Originally discovered in CD4+ cells (328), the TIL1383I TCR has a high enough
affinity for hTyr368-376 that it can elicit recognition of the HLA-A2 presented peptide
without the presence of the CD8 co-receptor. Subsequently, this TCR was successfully
retrovirally transduced onto human donor peripheral blood lymphocytes (70). Both
transduced CD4 and CD8 cells demonstrated antigen recognition, and CD8 cells
additionally demonstrated HLA-A2 and Tyrosinase specific cytolytic functionality (70).

Activation-Induced Cell Death
Therapeutic T cells which have undergone a REP in order to achieve the necessary
quantity of cells for infusion are susceptible to activation-induced cell death (AICD) upon
TCR restimulation in vitro (171), which likely limits their persistence upon encountering
tumor antigen when transferred in vivo. While AICD is likely counterproductive for
adoptive transfer therapy, it is a necessary mechanism of immune regulation in the
prevention of autoimmunity. During the context of a normal immune response, T cells
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are activated by three separate signals consisting of cognate MHC-presented peptide to
the TCR (signal 1), costimulatory receptor engagement such as CD28 ligation (signal 2),
and inflammatory cytokines that instruct the T cell towards the development of effector
functionality (signal 3). Once properly activated, T cells undergo clonal expansion and
move out into the periphery whereby they mount effector responses against infected
cells displaying their cognate antigen (330,331).
After activation and expansion of effector T cells, it is then necessary to prevent
damage to the host caused by either the continual production of inflammatory cytokines
or the potential onset of autoimmune or lymphoproliferative pathologies. As such, the
immune system negatively regulates the expansion of activated T cells by limiting their
persistence once the invading pathogen has been cleared (332). There are several
mechanisms that restrain the persistence of T cells once they have been activated to
undergo an immune response. As T cells undergo active replication in the process of
clonal expansion, their telomeres continually erode eventually imposing the “Hayflick
limit” of replicative senescence (333). T cells are also constrained by lack of cytokine
support by the mechanism of “cytokine withdrawal-induced death” (334). This type of
cell death has also been termed “activated cell autonomous death” as it occurs
independent of any TCR or death receptor signaling (335,336). Rather, as T cells no longer
receive cytokine support, they begin to undergo programmed cell death via the intrinsic
apoptotic pathway mediated by a threshold of pro-apoptotic Bcl-2 family of proteins
overcoming the resistance of anti-apoptotic factors (336).
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In contrast, another form of programmed cell death that regulates the persistence
of activated T cells is initiated by ligation of the TCR and is termed activation-induced cell
death (AICD). Ligation of the TCR is absolutely required for the onset of this type of cell
death and can occur via both αβ and γδ TCR subsets (337). The requirement of TCR
signaling has been confirmed by many studies which have demonstrated that mutations
in the ITAM signaling motifs of the CD3 co-receptor (338–340) and deletion of p56lck (341)
thwart the occurrence of cell death upon TCR restimulation.
As a mechanism of peripheral tolerance, AICD is exclusively constrained to cells
that have been previously activated via a primary TCR stimulus, as naïve T cells are
resistant to cell-death induced by TCR ligation (342). Moreover, signaling from the
activating cytokine IL-2 is also required to prime cells for AICD (343,344). Consequently,
T cells from IL-2 and IL-2Rα deficient mice are resistant to AICD (345).
Modulation of any of the three signals involved in T cell activation can determine
the susceptibly of an individual T cell towards AICD. A stronger TCR stimulus (signal 1),
either through a higher affinity TCR or concentration of antigen, makes a T cell more
susceptible to AICD (346,347). In parallel to TCR ligation, engagement of the costimulatory receptor CD28 (signal 2) can promote the proliferation of T cells through the
activation of NF-κB (348), enhancement of glycolytic metabolism (349), upregulation of
telomerase (350), as well as protection from AICD (351,352). Additionally, as T cells
undergo a REP, they lose CD28 expression, but gain expression of another co-stimulatory
receptor, 4-1BB, whose engagement also protects cells from AICD (171). However, such
co-stimulatory engagement is rarely found within the tumor microenvironment (353)
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leaving T cells that have trafficked to the tumor devoid of this protection. Consistent with
the role of AICD in immune-constraint, inflammatory “signal 3” cytokines such as IL-12
and IFNγ aid in priming T cells for AICD (354,355). However, other cytokines, such as IL-4
and IL-15, have been shown bolster the resistance of T cells to AICD (356,357).
Many reports in the literature assert that Fas death receptor signaling is an
integral part in the onset of AICD.

Indeed, Fas deficient mice have a massive

lymphoproliferative disorder indicating a Fas-critical deficiency in immune-regulation
(358,359). Moreover, Fas expression is upregulated during TCR restimulation (360).
However, multiple reports have shown that AICD still proceeds in the absence of Fas
signaling either by the lack of Fas receptor expression (361–364) or utilization of a FasL
blocking antibody (365,366) which suggests that Fas is not required for cell death to occur
following TCR restimulation (367). Moreover, the downstream signaling components of
AICD are not consistent with the requirement for FAS death receptor signaling. Fas
operates independently of ITAM signaling (368).

TCR restimulation results in the

accumulation of reactive oxygen species (369) which is required for the onset of AICD as
the ROS scavenger MnTBAP can protect T cells from death following TCR restimulation
(370). Conversely, FasL induced cell death operates independently of ROS signaling
(370,371). While Fas induced apoptosis is inherently dependent on caspase execution,
inhibition of caspases cannot block AICD, nor are caspases activated during AICD
(366,367,372,373). Moreover, the cell death morphology of AICD does not contain
apoptotic blebs but appears more necrotic in nature (367). Finally, small scale DNA
fragmentation consistent with an apoptotic phenotype is also absent from AICD
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(373,374). Instead, AICD presents with large scale DNA damage mediated by Apoptosis
Inducing Factor (AIF) (373). Thus, the cell death phenotype of TCR restimulated AICD is
emerging to be more consistent with programmed necrosis (or “necroptosis”) than
classical apoptosis (375). Consistently, RIPK1 and RIPK3, involved in the onset of
necroptosis (376), are induced during AICD, while conversely pharmacological inhibition
of necroptosis protects T cells from cell death following TCR restimulation (377).

T cell Receptor Generated ROS and Redox Regulation of Cellular Processes
Generation of ROS Upon TCR Stimulation
Ligation of the TCR results in the rapid generation of reactive oxygen species (ROS)
with both superoxide (O−
2 ) and hydrogen peroxide (H2O2) species being distinctly
generated within 15 minutes of TCR stimulation (369). In the cell, ROS are primarily
generated in the mitochondria as a byproduct of metabolism. Within the mitochondria,
Complex I and Complex III of the electron transport chain are major hubs of ROS
generation (378). Complex I emits superoxide into the mitochondrial matrix whereby it
is rapidly converted to hydrogen peroxide by the antioxidant enzyme manganese
superoxide dismutase (MnSOD/SOD2) (378). Complex III releases superoxide into both
the matrix and the intermembrane space (IMS) of the mitochondria (379,380). This
superoxide in the IMS then has the potential to be transported into cytosol of the cell,
without prior dismutation by MnSOD2, via voltage-dependent anion channels (381).
In the T cell, ROS has also been demonstrated to be a product of NADPH
(nicotinamide adenine dinucleotide phosphate) Oxidase, which has classically been
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characterized as responsible for the “respiratory burst” of pathogen killing free-radicals
in the innate immune system (382). However, the Laboratory of Mark Williams has
demonstrated NADPH Oxidase to also be relevant in the generation of ROS in the T cell.
Devadas, et al, blocked the generation of superoxide by either preincubation of T cells
with the NADPH Oxidase inhibitor diphenylene iodonium (383,384) or the overexpression
a dominant negative form of Rac1 (N17 Rac1), which has been implicated in the ROS
generating functionality of NADPH Oxidase (369,385). These data suggest a role for
NADPH Oxidase in the production of superoxide in T cells upon TCR ligation.
Subsequently, the lab demonstrated that T cells expressed mRNA for the NADPH Oxidase
subunits p22phox, p47phox, p67phox, and gp91phox and also had detectable protein expression
for the p47phox, p67phox, and gp91phox subunits (386). Moreover, T cells from mice deficient
in either p47phox or gp91phox NADPH Oxidase subunits have defective generation of ROS
when undergoing TCR stimulation, supporting the role of NADPH Oxidase in TCR
stimulation induced ROS generation (386).

Redox Regulation of Cellular Processes
Given the destructive nature of free radical species, the generation of ROS by T
cells has classically, and appropriately, been viewed in terms of regulating T cell survival
or death (387). Indeed, the scavenging of superoxide with the SOD mimic MnTBAP
protects cells from AICD (370). Moreover, blocking ROS production through the inhibition
of mitochondrial Complex I also protects T cells from AICD (388). However, more than
just being a blunt force of cell destruction, the levels of ROS can exert influence in the
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regulation of a wide array of cellular functions outside of the paradigm of cell death (389).
For instance, oxidative stress has long been known to be a determinant of T cell
proliferation. In general, the quenching of ROS through use of antioxidants has been
shown to imped the activation, proliferation, and IL-2 secretion of mitogen stimulated T
cells (390–393). Incubation of T cells with the Complex I inhibitor rotenone reduced ROS
as well as T cell proliferation, cytokine production, and reduction in the degranulation
marker CD107a, implying a decrease in cytolytic functionality (394). Disruption of
Complex III through a T cell specific knockout of the Complex III subunit RISP resulted in T
cells that were unable to undergo antigen-specific proliferation coinciding with defective
NFAT activation, IL-2 secretion, and expression of CD25 and CD69 activation markers
(395). Although, on the contrary, some reports have demonstrated that the exogenous
addition of pro-oxidants can also block T cell activation (396–398). And moreover,
decreasing a T cell’s antioxidant capacity through depletion of glutathione (GSH), through
the use of buthionine sulphoximine (BSO), can also thwart T cell proliferation (399–401).
The disagreement in these reports likely highlights the specific nature of the redox
regulation of cellular processes, as indeed ROS levels not only dictate whether a T cell will
die or proliferate but can have highly nuanced functional consequences for the T cell.
Mice with a T cell specific knockout of SOD2 present with elevated levels of mitochondrial
superoxide and a disruption in T cell thymic development rendering the mice more
susceptible to influenza challenge (402). In manipulating the redox environment after
thymic development, antioxidants can push a T cell towards an increase in the Th1
response (i.e. more IFNγ and TNFα) and a decrease in Th2 responses (i.e. less IL-4, IL-5)
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(403–405), and pro-oxidants can have the opposite effect favoring a Th2 phenotype at
the expense of Th1 (406,407). Consistently, the T cell specific deletion of the NADPH
Oxidase subunit p47phox by Jackson, et al resulted in an increase of IFNγ and IL-2 with a
concurrent decrease in IL-4 and IL-5 (386). This finding was further corroborated in a
subsequent report demonstrating reduced expression of the Th2 promoting transcription
factor Gata-3 in these p47phox deficient T cells (408,409).

The Cysteine Thiol Switch
Altogether, these studies affirm the importance of redox signaling in regulating a
diverse array of cellular outcomes. Of free radical species, hydrogen peroxide has
emerged as the chief signaling molecule (410).

Hydrogen peroxide has several

properties, particularly in contrast to superoxide, that make it an ideal molecule for
signaling. Hydrogen peroxide has a significantly longer half-life (1ms vs 1µs) than
superoxide (410). Moreover, the instability of superoxide is further compounded by its
rapid dismutation into hydrogen peroxide catalyzed by superoxide dismutase (SOD)
enzymes found in the cytoplasm (CuZnSOD/SOD1), the mitochondria (MnSOD/SOD2),
and extracellularly (SOD3) (411). Additionally, hydrogen peroxide has a relatively
tempered rate of oxidation which allows for a certain discernment in prioritizing which
protein residues it oxidizes, in contrast to a more reactive species, such as the hydroxyl
radical (OH•), that is more unsystematic in its oxidative activity, haphazardly attacking all
biomolecules (410,412).
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The preeminent target for hydrogen peroxide is the sulfur containing thiol moiety
(R-SH) located on cysteine residues, of which there seems to a be selective targeting of
certain cysteine thiols within the proteome (413). The reaction of hydrogen peroxide with
the sulfur thiol (R-SH) produces the oxidized sulfenic acid (R-SOH) through the process of
sulfenylation (414). Hydrogen peroxide oxidizes detoxifying enzymes, such as glutathione
peroxidase (GPx) or peroxiredoxin (Prx), with an elevated priority due to the presence of
catalytically advantageous thiols located within the active site of these enzymes that aid
in a more favorable reaction (415,416).

However, amongst less reactive cysteine

residues, it is still unclear how hydrogen peroxide discerns which residues to oxidize.
Though several, non-exclusive, guiding principles have emerged towards understanding
the selectivity of certain cysteine residues by hydrogen peroxide. Certainly, a detoxifying
enzyme may oxidize another cysteine residue as a result of its reaction with hydrogen
peroxide, such as the oxidation of the transcription factor Yap1 by GPx3 in yeast (417).
The localization of certain proteins relative to the production of hydrogen peroxide may
also influence the likelihood for oxidation (414,418). For example, the localization of
Nox4 (NADPH Oxidase 4) to the endoplasmic reticulum is key to the regulation via
oxidation of the ER resident protein PTP1B (419). Additionally, steric hindrance and the
polarity of adjacent residues can influence the pKa value of an individual cysteine towards
its reactivity with hydrogen peroxide (420).
The elucidation of proteins that are regulated by sulfenylation is ever evolving and
relevant for many different cellular functions (414). For instance, sulfenylation has been
implicated in the regulation of the PIP3/Akt proliferation pathway. PTEN, which represses
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phosphatidylinositol 3,4,5-trisphosphate (PIP3), and subsequent activation of the AKT
pathway, is inactivated via transient oxidation of its cysteine residues (421). Conversely,
maintaining the Cys296 and Cys310 residues of Akt1 in their reduced form has been shown
to be necessary for optimal Akt1 activation (422). Apoptosis can be regulated through
the inactivation of the anti-apoptotic protein Bcl-2 by oxidation of its Cys158 and Cys229
residues (423). The status of protein ubiquitination can also be regulated through the
cysteine oxidization induced inactivation of deubiquitinases such as USP1 or A20
(424,425). Cysteine oxidation can also provide critical feedback to launch antioxidant
protective measures within the cell during periods of increasing oxidative stress. The
transcription factor Nrf2 coordinates the upregulation of many antioxidant genes termed
the “antioxidant response element” and is negatively repressed via nuclear exclusion and
ubiquitination mediated proteasomal degradation by Keap1 (426). Consequently, Keap1
can be inactivated through oxidation of its Cys273 and Cys288 residues, allowing for the
liberation of Nrf2 to traffic to the nucleus and transcribe pro-antioxidant genes (427).
For the T cell, sulfenylation based signaling is emerging as a key regulator of
activation. Oxidation of the Cys195 residue of the calcium channel protein ORAI1 can
inactivate it, impairing calcium influx during TCR activation (428).

Moreover, the

transcription factor NF-κB, necessary for T cell activation, requires that the Cys62 residue
of its p50 subunit be in its reduced state for its DNA binding activity (429). Upon TCR
stimulation, Michalek, et al. demonstrated that there is a global increase in the level of
cysteine sulfenic acid (430). Moreover, treating T cells with dimedone, which covalently
binds to cysteine sulfenic acid and does not allow further modification (431), prevented
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T cell proliferation, implying that both the formation of sulfenic acid and its reversal are
critical for the induction of T cell proliferation (430). The same study demonstrated that
TCR stimulation results in cysteine sulfenic acid modification of the protein tyrosine
phosphatases (PTP) SHP-1 and SHP-2 (430). This is consistent with previous studies that
have shown sulfenylation to be a critical regulator of global PTP activity (432) as PTPs have
a redox sensitive cysteine in their catalytic core (433). Moreover, in the case of SH2domain containing PTPs, such as SHP-1 and SHP-2, unique regulatory “backdoor”
cysteines have been identified which participate in disulfide bond formation critical for
reversible oxidation (434).
Beyond sulfenylation, cysteines can achieve higher oxidative states such as sulfinic
acid (R-SO2H) and sulfonic acid (R-SO3H) which are less amenable towards being reduced
back towards a neutral thiol. Though, sulfiredoxin can catalyze the reduction of sulfinic
acid with emerging signaling consequences (435). Sulfonic acid is generally regarded as
an irreversibly oxidized state.

Additionally, more aggressive oxidants, such as

peroxynitrite or the hydroxyl radical, can oxidize thiols into thiyl radicals (436). In order
to protect proteins from further oxidation, residues can undergo an S-thiolation
modification whereby mixed disulfides are formed between the thiol residue and another
low molecular weight thiol (437). When that particular low molecule weight thiol is
glutathione (GSH), the modification is termed S-glutathionylation (438). The overall
process of S-glutathionylation can be reversed by deglutathionylation facilitated by
thioredoxin, glutaredoxin, (439), or sulfiredoxin (440).

The reversible nature of

glutathionylation allows it to serve in a signaling capacity beyond antioxidant protection.
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Glutathionylation has been shown to regulate a diverse array of cellular functions.
Glutathionylation promotes the inactivation of NF-κB both directly on the Cys62 residue
of its p50 subunit (441) as well as upstream inactivation of IKKβ by glutathionylation of its
Cys179 residue (442). Additionally the stress activated protein kinase MEKK1, also
implicated in NF-κB signaling (443), is inhibited by glutathionylation on Cys1238 (444).
Conversely, glutathionylation promotes Akt signaling by both activating upstream Ras on
Cys118 (445) and inactivating PTEN (446). The tumor suppressor p53 is inactivated by
glutathionylation of cysteines within its DNA binding domain, which prevent DNA binding
and the necessary tetramerization of p53. (447). The cytoskeleton can also be regulated
by glutathionylation as the rate of actin polymerization is reduced upon glutathionylation
of its Cys374 residue (448). Glutathionylation in the α-rings aids to open the 20S
proteasome facilitating the proteasomal degradation of proteins (449). Apoptosis can be
promoted by glutathionylation of the Fas death receptor on its Cys294 residue which
facilities its transport to lipid rafts, encouraging the formation of the death-inducing
signaling complex (450). However, on the contrary, the cell death executioner Caspase 3
can be inactivated by glutathionylation (451). Glutathionylation of eNOS on Cys689 and
Cys908 switches it from producing nitric oxide (NO) to superoxide (452). Additionally,
glutathionylation can also regulate ion channels as it inhibits both the Kir4.1-Kir5.1 inward
rectifier K+ channel (by glutathionylation of the Cys158 residue of the Kir5.1 subunit) (453)
and the Na,K-ATPase Na+K+ antiporter by an increase in the glutathionylation of multiple
residues of its α-subunit (454). Within the mitochondria, glutathionylation of Complex I
leads to a decrease of electron transfer activity with an inverse increase in ROS production
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(455), as well as inhibition of several metabolic enzymes: α-ketoglutarate dehydrogenase
(456), GAPDH (457), aldose reductase (458), succinyl-CoA transferase (459). As such,
there are a diverse array of cellular process which are regulated by either sulfenylation or
glutathionylation of cysteines which could like be altered modulating the redox
environment or glutathione concentration in the cell by treatment with the glutathione
pro-drug N-acetyl cysteine.

N-acetyl cysteine
N-acetyl cysteine (NAC) is a derivative of the sulfhydryl group containing amino
acid cysteine whereby an acetyl group has been attached to the nitrogen atom of cysteine
(Fig. 1). This modification enhances the stability of cysteine, which is rapidly oxidized in
solution to form the biologically inactive Cys-Cys disulfide dimer Cystine. The acetyl
moiety of NAC makes it less reactive than cysteine and thereby less susceptible to this
oxidation/dimerization (460).
Biochemically, NAC has been reported to have four primary mechanisms of action.
First, NAC’s primary benefit to the cell is to serve as a pro-drug for glutathione (GSH)
synthesis. NAC contributes the cysteine, which is then conjoined to glutamate via the
enzyme glutamate-cysteine ligase. Subsequently, glycine is then added via the enzyme
GSH synthase to complete the GSH tri-peptide. GSH synthesis is self-regulated as GSH
itself inhibits glutamate-cysteine ligase (461,462). Therefore, NAC is only beneficial in this
regard in situations where there is both depleted levels of GSH and sufficient levels of
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Figure 1. Chemical structure of N-acetyl cysteine
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enzymes involved in GSH synthesis are maintained (460). In such situations, where there
are competent levels of GSH, NAC administration can alternatively lead to an increase in
cysteine levels in cells and in the plasma (463,464). Second, NAC is commonly regarded
as an “antioxidant” and has often been shown to modulate oxidative stress in the
literature (465). However, the interpretation of NAC as a direct reducing agent is complex
as NAC is approximately 10-fold less efficient as a reducing agent than GSH (466) and both
NAC and GSH are orders-of-magnitude less efficient at resolving oxidative stress than
antioxidant enzymes such as superoxide dismutase (467).

However, thirdly, NAC has

been well documented to be important for the direct reduction of disulfide bonds. This
has been specifically clinically relevant in bronchial disorders whereby the disruption of
disulfide bonds in the glycoprotein matrix of mucus by NAC aids in reducing mucosal
viscosity (468).

Moreover, such modification of cysteine structure can have

consequences in terms of alteration of ligand binding and structure-based functionality
of proteins (465). Lastly, NAC can directly bind and chelate metals. Particularly, NAC has
been documented to chelate the food and environmental contaminate methylmercury
(469). Administration of NAC increases the urinary excretion of methylmercury in rats in
a dose dependent manner (470). NAC also protects against mercury (471,472), cadmium
(473), potassium dichromate, lead tetraacetate (474), and copper poising (475) in rat
models as well.
NAC can be administered orally, intravenously, or by aerosol for use as an antimucosal agent. NAC, administered orally, is quickly metabolized in the liver rendering
just 6-10% bioavailability in the plasma with a Tmax of only 1-2 hrs (476). Intravenous
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administration of NAC produces a higher initial concentration in the plasma (300µmol/L
i.v. versus 19.9µmol/L oral) (477). However, retention of NAC in the plasma is not much
improved with a half-life of only 2.27 hrs (477) likely due to the rapid oxidation of NAC in
the plasma into NAC-cysteine and NAC-NAC formations (478).
Radiolabel studies suggest that NAC does not readily cross the cell membrane
(479) likely due to the influence of negatively charged -COOH and -SH groups. However,
protonation studies suggest that an acidic environment such as the stomach may put NAC
at a more neutral isoform (480), though this has not been verified experimentally. NAC
has primarily been reported to enter the cell via the System X C- cysteine-glutamate
antiporter (481,482), though other transporters such as the System ASC (alanine-serinecysteine) transporter system may also facilitate the transport of NAC (483).
The clinical utility of NAC was first demonstrated in the 1960s as an effective
mucolytic agent in cystic fibrosis (CF) when used as an inhalant via breaking up disulfide
bridges in the glycoproteins of the mucus (468,484). Beyond providing aid in the
clearance of mucus, NAC can also benefit CF patients through the elevation of GSH levels
which are notably depressed in the epithelial lining fluid (485) and the bronchoalveolar
lavage fluid of CF patients (486). Additionally, NAC has also been shown to be beneficial
in other respiratory conditions. NAC has been shown to reduce bronchial hypersecretion,
exacerbations, and re-hospitalization episodes in chronic bronchitis and COPD (487–490).
However, NAC does not prevent the overall decline of lung function associated with COPD
(491). NAC also protects against smoking induced injury of endothelial cells (492) and the
lungs of rats exposed to cigarette smoke (493).
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After its initial use as an anti-mucolytic agent, the other most notable and longstanding use of NAC in the clinic has been to ameliorate the toxicity caused by
acetaminophen poisoning (494). The metabolism of acetaminophen produces the byproduct N-aceytl-p-benzoquinone imine (NAPQI) which is toxic to the cell (495,496). GSH
neutralizes NAPQI back to acetaminophen; however, overwhelming this system via
overdose can cause a rapid depletion of GSH allowing for NAPQI to accumulate in toxicity
(497). As such, replenishment of GSH via NAC supplementation is thought to counteract
this toxicity (498,499).

Resolution of toxicity is most effective when NAC can be

administered within 8 hours of overdose (500) with no notable difference in efficacy
between oral and intravenous administration (501).
NAC enjoys a fairly benign safety profile even at very high doses (such as used in
the case of acetaminophen poisoning).

Most side-effects come about through

intravenous administration where mild nausea and gastrointestinal symptoms can occur
(489).

More severe cases of anaphylactic reactions have been reported such as

bronchospasm, angioedema, and hypotension, although attributed to an overestimation
of i.v. dosage or with asthmatic patients (502). And though extraordinarily rare, a handful
of fatal events have been reported with improper dosing of NAC (503).
NAC can be beneficial in certain cardiovascular applications. The cardiovascular
complications of hyperhomocysteinaemia can be prevented by the conversion of
homocysteine to methionine by NAC (504). Administration of NAC attenuates damage
caused by myocardial infarction (505,506) in the clinic and damage caused by stroke in a
rat model (507) most likely through the alleviation of ischemia/reperfusion injury (508).
47

Additionally, NAC has been shown to improve overall vascular health by preventing
oxidative stress caused atherosclerotic plaques (509), inhibition of adhesion molecules
such as ICAM and VCAM (510,511), thwarts platelet aggregation (512) and aids in
vasodilation (513) particularly through the attenuation of angiotensin (514) and increased
bioavailability of the vasodilator NO (515) through enhanced eNOS expression (516).
NAC has even been shown to be beneficial in certain neuropsychiatric disorders
both by GSH replenishment where GSH depletion associates with a neuropsychiatric
disorder (517,518) and also by increasing the extracellular levels of glutatmate,
stimulating the release of vesicular dopamine via group II metabotropic glutamate
receptors (519). In various trials, NAC has been able to demonstrate a beneficial effect of
the symptoms associated of schizophrenia (520,521), obsessive-compulsive disorder
(522), autism (523), and bi-polar depression (524). Additionally, administration of NAC
has reduced addictive behavior associated with nicotine (525), cannabis (526), cocaine
(527), methamphetamine (528), and even gambling (529).
Within the immune system, administration of NAC has exhibited a diversity of
outcomes.

For instance, NAC has been shown to mediate certain autoimmune

parameters such suppression of anti-DNA antibodies and enhancing survival in a lupus
mouse model (530) and quelling T cell hyporesponsiveness in rheumatoid arthritis
patients (531) as well as reduction in TNFα-induced RA related cytokines through the
inhibition of NF-κB (532–534). Additionally, administration of NAC has also been shown
to attenuate neutrophil chemotaxis and ROS production (535,536). However, in other
studies, NAC has been shown to enhance T cell functionality. Administration of NAC in
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vitro can increase T cell secretion of IL-2 (537) as well as T cell proliferation (538).
Moreover, NAC has also been shown to functionally restore the immune system in
advanced cancer patients (539).
As the progression of HIV exacerbates the depletion in GSH levels, and as GSH
levels inversely correlate with patient prognosis, it was proposed in the 1990s that NAC
supplementation may be of benefit to HIV patients (540,541). Several studies have
demonstrated a modest restoration in glutathione levels and immune function with NAC
administration (542–544). However, no studies have demonstrated a prolonged benefit,
and other studies have contradicted the utility of NAC administration in the ability to
increase GSH levels in HIV patients (545). Altogether, benefit of NAC administration is
likely transient at best as part of the pathology of HIV is interruption of the GSH synthesis
machinery likely through a HIV-Tat mediated mechanism (545–548).
Administration of NAC may also affect the antigen-presenting compartment of the
immune system as well. Cysteine supplementation to T cells by APCs has been shown to
be critical for optimal T cell activation and proliferation (549,550) and endows them with
protection against oxidative stress (551,552). Moreover, elevated intracellular GSH
content has been shown to correlate with enhanced pro-inflammatory IFNγ secretion by
dendritic cells and macrophages (553). As such, disruption of GSH synthesis in dendritic
cells and T cells is one mechanism Tregs use to suppress T cell activation (554). However,
some studies have suggested NAC may play a detrimental role as NAC has been shown to
suppress dendritic cell activation by its repression of NF-κB as well as reduce expression
of CD86 and CD40 co-stimulatory molecules (555). Altogether, studies with NAC have
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demonstrated it can constitute a wide range of effects beyond simply being an
antioxidant. However, most of these reported observations with NAC, some of which
demonstrate contradictory outcomes, must be appreciated at the specific dosage and cell
type or disease context reported.

p53
The tumor suppressor p53 has been implicated in the onset of AICD. In 2013,
Chhabra & Mukherji demonstrated that the p53-inhibitor, pifithrin-u, protects T cells from
cell death following TCR restimulation (556). The implication that p53 is involved in AICD
is consistent with its role as a master regulator of cell death. First discovered in 1979
(557), p53 was recognized in the late 1980s to be a tumor suppressor (558–560). Since
then, p53 has emerged to be one of the chief tumor suppressors earning the title as the
“Guardian of the Genome” (561). The critical role of p53 in tumor suppression is
evidenced by the fact that it has either been deleted or functionally inactivated in nearly
half of all cancers (562,563). Consistently, p53-knockout mice quickly develop and
succumb to lymphomas at approximately 6 months of age (564,565). In melanoma, p53
seems to be a hurdle in the initial dysplasia of benign nevi (566). In more advanced
melanoma, p53 has a low level of mutations, but seems to be overexpressed (567).
The cell death functions of p53 have been characterized both within and outside
of the nucleus. Within the nucleus, p53 functions as a transcription factor by coordinating
the cellular response to a stress insult. Generally responding to DNA damage, p53
preferentially upregulates DNA repair genes while halting cell cycle progression (568),
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giving the cell an opportunity to resolve the stress and repair any damage. However, if
resolution of the stress insult cannot be accomplished, p53 then begins to target cell
death genes such as Bax, Bak, Puma, etc (568). Outside of the nucleus, p53 functions in a
transcriptionally-independent manner. It can promote the oligomerization of Bax and
Bak at the outer membrane of the mitochondria towards the formation of the
mitochondrial outer membrane permeabilization, and it can also sequester Bcl-2 and BclxL which antagonize Bax/Bak oligomerization (569,570).
In unstressed cells, p53 levels are repressed through proteasomal degradation via
the E3-ubiquitin ligase HDM2 whereby it binds and ubiquitinates the Transactivation
Domain 1 of p53 targeting it for proteasomal degradation (571). In response to stress,
p53 is phosphorylated, and the resulting conformational change results in dissociation
from HDM2 (572,573). One of the primary residues to undergo phosphorylation in
response to cellular stress (particularly DNA damage) is Serine-15 (574). In addition to
facilitating the dissociation of p53 from HDM2, phosphorylation on Ser15 also promotes
accumulation of p53 in the nucleus, another hallmark of p53 activation (Fig. 2) (575,576).
Ser15 is located within a nuclear localization signal (577) as well as a nuclear export signal
motif, which is inactivated via Ser15 phosphorylation retaining p53 in the nucleus (578).
Furthermore, the phosphorylation of Ser15 is necessary for p53 functionality as an alanine
substitution mutation protects cells from death following genotoxic stress (579).
Moreover, cytoplasmic sequestration is one common mechanism whereby tumor cells
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Figure 2. p53 is activated by phosphorylation and nuclear accumulation. (1) In
unstressed cells, the E3 ubiquitin ligase MDM2 (HDM2 in the human) ubiquitnates p53
resulting in proteasomal degradation. (2) DNA damage results in the activation via
autophosphorylation of ATM on Ser1981 (3) Activation of ATM results in the
downstream phosphorylation of p53 on one or more of its N-terminal serines which
promotes a conformational change allowing it to dissociate from MDM2. (4) p53
accumulates in the nucleus whereby it begins to promote the transcription of cell cycle
arrest and repair genes, and then, if the stress cannot be resolved, p53 ultimately
targets pro cell death genes (i.e. BAX, NOXA, PUMA) for transcription [Adapted from
(580)].
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deactivate p53 functionality in the nucleus, further supporting a cell death role of nuclear
p53 (581).
p53 seems to play more complex role in the immune system than simply
maintaining genomic integrity. Watanabe et al. demonstrated that p53 is critical to
blocking non-specific IL-2 driven T cell proliferation, enforcing the requirement of antigenspecific TCR ligation for proliferation (582). p53 has also been shown to regulate
autoimmunity. p53 promotes the differentiation of Tregs by conversely dampening the
differentiation of Th17 cells through repression of STAT3 (583).

Consistently,

autoimmunity is exaggerated where there is a loss of p53 expression or function such as
in arthritis (584–588), multiple sclerosis, (589,590), and Crohn’s disease (591,592).

ATM
The chief kinase responsible for phosphorylation of p53 is Ataxia Telangiectasia
Mutated (ATM). ATM derives its name from being functionally inactivated in the
neurodegenerative disease Ataxia Telangiectasia (593). One of the many consequences
of Ataxia Telangiectasia is a high rate of lymphoid malignancies, which is consistent with
the failure of T cells from Ataxia patients to undergo cell death in response to DNA
damaging insults (594). DNA damage, particularly the presence of double-strand DNA
breaks (DSB), activates ATM. In response to DSB, the DNA damage sensing MRN complex
targets ATM to the lesion, resulting in the autophosphorylation of ATM on Serine 1981.
In its inactive form, ATM is in a dimer conformation, and autophosphorylation on Ser1981
causes it to disassociate into its active, monomeric form (p-ATM) which engages in
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downstream kinase activity, such as phosphorylation of p53 on Ser15 (595).
Consequently, T cells from Ataxia patients have reduced levels of p-p53Ser15 upon
genotoxic stress (596).
However, while ATM has primarily been regarded to be activated by DNA damage,
several reports have demonstrated that ATM can be activated by oxidative stress (597)
or by hypoxia (598) in the absence of DNA damage. As such, activation of ATM alone is
not sufficient to suggest the onset of DNA damage within a cell. Additional confirmation,
such as the presence of γH2AX foci, should be examined as well to confirm that ATM is
indeed being activated by bona fide DNA damage (599).

T cell Exhaustion and PD-1
An acute immune response effectively removes the foreign pathogen and its
associated antigens allowing for contraction with a subset of cells remaining as memory
cells. However, chronic infections or cancers, such as melanoma (600), which have
evaded an initial immune response, are not resolved resulting in the continuation of
antigen engaging the immune system (601). Such chronic stimulation leads to T cells
exhibiting an exhausted phenotype denoted by lack of adequate effector functionality
(602,603). Additionally, exhausted T cells express key inhibitory receptors such as PD-1,
TIM-3, and/or LAG-3 (604).
T cells which have trafficked to the tumor microenvironment are reported to be
exhausted even in the early stages of cancer (605), and exhaustion involves epigenetic
modification to the T cell (606,607). Simply removing antigen does not revert an
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exhausted phenotype (608). As such, PD-1 levels remain high on T cells from HIV patients
even when viral load is significantly suppressed through retroviral therapy (606).
However, modulation of inhibitory receptor signaling, such as PD-1/PD-L1 blockade can
restore cells from an exhausted phenotype (609) given that PD-1 expression is not too
high (610).
Programmed Death-1 (PD-1), aptly named first being discovered in T cells
undergoing cell death, (611) is the most characterized marker of T cell exhaustion. PD-1
is initially induced upon TCR stimulation in T cells (612). During an acute infection, PD-1
levels peak at around Day 6 after stimulus and then contract back to basal levels.
However, during chronic infection, where there is continued antigenic stimulation, PD-1
levels remain elevated (609). As such, PD-1 is expressed on viral-specific cells of patients
with HIV (613), hepatitis B (614), and hepatitis C (615). Additionally, as the melanoma
tumor microenvironment provides a source for continuous antigen exposure, PD-1
reliably marks melanoma specific TILs within the tumor microenvironment (616).
Expression of PD-1 is promoted by the transcription factor EOMES and repressed
by T-bet expression (617,618). Ligands for PD-1 are PD-L1 (619) and PD-L2 (620). PD-L1
is expressed on melanoma cells (621). Ligation of PD-1 during activation can thwart
proliferation, cytokine production, cytolytic function and impair T cell survival. PD-1
signaling attenuates phosphorylation of TCR signaling elements CD3ζ and ZAP70, reduces
production of IL-2 (622), and depresses the PI3K-Akt cell proliferation pathway (623).
Consistent with its involvement in negative immune regulation, PD-1 knockout
mice demonstrate an autoimmune phenotype via autoimmune dilated cardiomyopathy
55

(624), lupus-like disease (625) and are more susceptible to experimental autoimmune
encephalomyelitis (626). Accordingly, mutational defects in PD-1 have been associated
with human disease conditions such as multiple sclerosis (627), lupus (628), and Type I
diabetes (629). Conversely, PD-1 deficient T cells demonstrate enhanced B16 tumor
control in a murine adoptive transfer model (630). Together, these observations suggest
that active PD-1 pathways quell the functionality of T cells.

Foxo1
Expression of PD-1 is regulated upstream, in part, by the activity of the
transcription factor Foxo1 (631). Foxo1 (Forkhead Box O1) was discovered in 1993 (632)
and has primarily been regarded as transcription factor acting as a tumor suppressor
(633). For instance, Foxo1 can be activated via DNA damage in the cell and regulates cell
death as siRNA knockdown of Foxo1 protects cells from DNA damage induced cell death
(634).
As a transcription factor, Foxo1 is primarily regulated by its subcellular location in
relation to the nucleus. Foxo1 is chiefly inactivated via phosphorylation by Akt at its
Thr23, Ser256, and Ser319 residues. Phosphorylation of Foxo1 causes it to bind with 143-3 proteins sequestering it in the cytoplasm (635–637) in part through blockade of
Foxo1’s nuclear localization signals (638). Additionally, Akt mediated phosphorylation of
Foxo1 can be enhanced by other post-translational modifications such as acetylation,
which also interferes with its ability to bind to DNA (639). Moreover, beyond restricting
nuclear access, sustained Akt signaling can also promote the ubiquitination and
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subsequent proteasomal degradation of Foxo1 (640,641) via Skp2 of the Skp1/culin 1/Fbox E3 ligase complex (642).
Activation of PI3K-Akt pathways during the initial activation of T cells results in the
nuclear exclusion and inactivation of Foxo1 (643). However, after this initial repression
of Foxo1 during T cell activation, studies over the past decade have demonstrated that
the subsequent regulation of Foxo1 expression has major implications for T cell
differential fate. For instance, differentiation of T follicular helper cells in response to
ICOS signaling is dependent on the inactivation of Foxo1 (644). Memory markers and/or
trafficking molecules such as CD62L, IL-7Rα, and CCR7 are amongst Foxo1 target genes
(645,646). As such, Foxo1 has been shown to promote the differentiation of memory T
cells (647) in part via the repression of T-bet and promotion of EOMES transcription
factors (648,649). Consequently, repression of Foxo1 promotes T-bet expression and
differentiation into effector cells including the expression of the cytotoxic effector
molecule granzyme B (648). Concurrently, Foxo1 promotes the generation of Tregs with
the T cell specific knockout of Foxo1 resulting in defective development of both thymic
derived and inducible Tregs. As a consequence, these mice present with an exaggerated
autoimmune phenotype characterized by enhanced anti-nuclear antibody production,
organ infiltration by lymphocytes, and the onset of exocrine pancreatitis and hind limb
paralysis (650,651). Conversely, Foxo1 represses Th17 differentiation through inhibition
of RORγt (652). Additionally, Foxo1 expression has been shown to associate with
exhausted T cells. Chronically stimulated exhausted T cells have more nuclear active
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Foxo1 than acute stimulated cells, and moreover, Foxo1 promotes the expression of the
exhaustion-associated transcription factor EOMES and inhibitory receptor PD-1 (631).

Concluding Remarks
The adoptive transfer of melanoma specific T cells has demonstrated a substantial
improvement in outcomes, and even curative potential, for patients with late stage
metastatic melanoma (219). However, the success of therapy has largely been dependent
on the quality of the infused cells, particularly the ability of the cells to persist and
continue to control tumor once they are transferred. The rapid expansion of T cells
pushes the activation status of these cells more towards a terminally differentiated
effector phenotype (170) which enhances their susceptibility to AICD when the cells are
restimulated with tumor antigen (171).

The ROS that are generated upon TCR

restimulation (369) are a critical component in the onset of this type of programmed cell
death (370). However, ROS generation has also been characterized as a necessary
secondary messenger in lymphocyte activation (410). Therefore, it is necessary to further
elucidate what pathways are responsible in escalating ROS accumulation from benign
messenger to cell executioner in the context of AICD.
The glutathione pro-drug NAC has been shown to protect T cells from AICD and
increase their persistence when transferred into a non-tumor bearing host (653).
However, it has not been demonstrated whether this protection from AICD afforded by
NAC is transient or if NAC provides a durable enhancement in phenotype that would be
of benefit upon encounter with tumor antigen in a melanoma challenged host. As NAC
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has previously demonstrated a wide range of phenotypic improvements for cultured T
cells such as enhanced antioxidant capacity, proliferation potential, cytokine production,
and improvement in the functional capacity of cells derived from advanced staged cancer
patients (537,539,653,654), we reasonably hypothesize that culturing melanoma specific
T cells in NAC prior to adoptive would improve their overall anti-melanoma performance,
in part, through a reduced susceptibility to AICD.

59

CHAPTER 2 - TCR RESTIMULATION RESULTS IN ACTIVATION OF THE DNA DAMAGE
RESPONSE PATHWAY IN THE ONSET OF ACTIVATION-INDUCED CELL DEATH

Introduction
Therapeutic T cells which have been subjected to a rapid expansion protocol (REP)
are susceptible to activation-induced cell death (AICD) when restimulated in vitro with
tumor antigen (171). As such, AICD likely restricts the durability of transferred T cells to
persist and mount anti-tumor cytolytic effector functions in vivo, curtailing their overall
abundance and therapeutic efficacy. AICD, which is triggered by restimulation of the T
cell receptor (TCR) on a previously activated T cell, is independent of death receptor
signaling and the downstream activation of caspases, but is dependent on the
accumulation of reactive oxygen species (ROS) and activation of c-Jun NH2-terminal
kinase (JNK) (366,370). Moreover, pharmacological inhibition of p53, a chief cell death
regulator downstream of JNK and ROS (655), by pifithrin-α (Mehrotra Lab, unpublished
data) and pifithrin-µ (556), has been shown to protect T cells from AICD.
However, off-target effects cannot be excluded from observations generated with
pharmacological inhibitors. Pifithrin-α confers protection to both p53 null and competent
cells from topoisomerase induced apoptosis (656), and pifithrin-µ has been additionally
characterized as an HSP70 inhibitor advancing protein aggregation induced cell death
(657). As such, this aim embarked to directly confirm the role of p53 in AICD by use of
the p53 knockout mouse (658). The role of p53 during AICD in human cells was
additionally explored by investigating two hallmarks of p53 activation: the
phosphorylation status of p53 and its accumulation in the nucleus (572,659).
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Furthermore, these observations acted as “barcode” (568) leading to the novel discovery
that the DNA damage response pathway is activated in T cells upon TCR restimulation
induced cell death.

T cells void of p53 are less susceptible to AICD
To directly determine the role of p53 in AICD, the p53-knockout (p53KO) mouse
was utilized (658). In order to make findings more relevant in a melanoma antigenspecific model, p53KO mice were crossbred with the h3T mouse to generate a h3T+p53KO
strain of mice. T cells from h3T mice constitutively express the human TIL1383I TCR
conferring the ability of T cells to recognize and mount a cytolytic response against
hTyr368-376 expressing melanoma cells in a HLA-A2 restricted manner (660). To ensure
that deletion of p53 did not interfere with the functionality of T cells, splenocytes from
h3T+/p53KO mice and h3T+/p53WT littermate controls were assessed for their ability to
recognize antigen as determined by the expression of activation markers and secretion of
IFNγ.

When stimulated overnight with hTyr368-376 cognate peptide, there was no

significant difference in the expression of CD25 or CD69 activation markers between
splenocytes harvested from h3T+/p53KO mice and those derived from h3T+/p53WT controls
(Fig. 3). However, splenocytes from h3T+/p53KO mice did have a significant increase
(~62.3%) in the amount of IFNγ secreted when restimulated with hTyr368-376 pulsed T2
cells in comparison to splenocytes from h3T+/p53WT littermates (Fig. 4). Together, these
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Figure 3. p53 status does not alter expression of CD25 and CD69 activation markers.
Freshly isolated splenocytes from h3T+/p53WT and h3T+/p53KO mice were co-cultured at
a 1:1 ratio overnight with T2 cells alone (no peptide) or T2 cells pulsed with either Mart
(1.0µg/mL) or hTyr368-376 (1.0µg/mL) peptide. After overnight co-culture, cells were
then stained with fluorochrome conjugated antibodies for (A) CD25 or (B) CD69. Left
panels display representative contour plot of Vβ12+CD8+ gated cells for each indicated
marker. Right panels are mean ± SEM of percent positive cells for each indicated marker
in Vβ12+CD8+ gated cells of n=5.
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Figure 4. Lack of p53 increases m-IFNγ cytokine secretion. Freshly isolated splenocytes
from h3T+/p53WT and h3T+/p53KO mice were co-cultured overnight at a 1:1 ratio with T2
cells alone (no peptide) or T2 cells pulsed with either Mart (1.0µg/mL) or hTyr368-376
(0.1µg/mL or 1.0µg/mL) peptide. Supernatants were collected and analyzed for m-IFNγ
concentration (pg/mL) via ELISA. Displayed is mean ± SEM of m-IFNγ (n=5, *p<0.05,
**p<0.01).
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data affirm that T cells derived from h3T+/p53KO are not defective in their ability to
recognize antigen.
To determine if p53 status altered T cell susceptibility to AICD, freshly isolated
splenocytes from h3T+/p53KO and h3T+/p53WT mice were activated for 48 hours with
plate-bound anti-CD3 and anti-CD28, and then subsequently washed, rested overnight,
and restimulated with hTyr368-376 pulsed T2 cells. After 4 hours of peptide restimulation,
T cells were stained with Annexin V, which binds to phosphatidylserine on the outer
plasma membrane of the cell. Phosphatidylserine is normally restrained to the inside of
the cell but is exposed on the surface when a cell losses plasma membrane asymmetry in
the early phase of cell death (661). Restimulation with hTyr368-376 for 4 hours caused an
increase in Annexin V binding. T cells co-stained with 7-aminoactinomycin D (7-AAD), a
membrane impermeant dye that stains cells with compromised plasma membrane
integrity occurring in late-stage cell death (662), did not result in an increase in 7-AAD
staining (Fig. 5a), indicating that 4 hours of peptide stimulation within our model system
captured cells in the early stages of cell death kinetics. Splenocytes from h3T+/p53WT
mice, when restimulated with hTyr368-376 peptide pulsed T2 cells, exhibited a ~2.7-fold
higher level of Annexin V than those restimulated by Mart control peptide. However,
splenocytes from h3T+/p53KO mice demonstrated resistance to AICD as they consistently
exhibited an approximately 17% decrease in Annexin V staining than their h3T+/p53WT
littermate counterparts (Fig. 5).
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Figure 5. Presence of p53 exacerbates cell death upon TCR restimulation. Splenocytes
from h3T+/p53WT and h3T+/p53KO mice were activated for 48 hrs with plate-bound antiCD3 (1µg/mL) and anti-CD28 (2µg/mL), rested overnight, and then restimulated by coculture at a 1:1 ratio with T2 cells pulsed with either Mart (1.0µg/mL) or hTyr368-376
(1.0µg/mL) peptide for 4 hrs. (A) Representative flow plot of Annexin V and 7AAD
expression following restimulation in Vβ12+CD8+ gated cells in representative
experiment. (B) Quantification of mean ± SEM of fold change (hTyr/Mart) in Annexin V
MFI expression in Vβ12+CD8+ gated cells (n=11, **p<0.01).
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To further determine if protection afforded by p53 knockdown was relevant in the
context of T cells that are transduced with an antigen-specific TCR, splenocytes from p53knockout mice (and wild type controls) were activated and transduced with the TIL1383I
TCR. Consistent with results observed in the h3T native TCR model, restimulation of
transduced T cells with hTyr368-376 peptide demonstrated a significant protection
(p=0.025) for p53KO cells compared to p53WT cells. Additionally, TIL1383I TCR transduced
murine T cells were restimulated with the HLA-A2 expressing B16(A2) murine melanoma
cell line to undergo AICD relative to HLA-A2‒ B16 cells as a control. p53KO transduced T
cells exhibited a 25.7% decrease in Annexin V expression when restimulated with HLA-A2
matched B16(A2) cells compared to p53WT cells (Fig. 6). Together, these data indicate
that ablation of p53 results in a partial, but significant, reduction in AICD susceptibility
suggesting that p53 is likely involved in the onset of AICD and is relevant for both native
expressing TCRs and transduced engineered cells.

p53 is activated via phosphorylation and accumulation in the nucleus
Protection of T cells from AICD via p53 deletion prompted the investigation into
the activation status of p53 upon TCR restimulation. An essential hallmark of initial p53
activation is the phosphorylation of one or more of its N-terminal serines, which facilitates
the dissociation from its chief negative regulator HDM2 (572,573). To determine the
phosphorylation status of p53 during AICD in human cells, PBMCs which were previously
activated with plate-bound anti-CD3 and anti-CD28, were invoked to undergo AICD
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Figure 6. TIL1383I TCR transduced p53KO mouse splenocytes are protected from AICD.
WT and p53KO mice were activated (with anti-CD3 & anti-CD28) and transduced with
the TIL1383I TCR. Cells were cultured 3 more days after transduction and then
restimulated by co-culture at a 1:1 ratio with T2 cells pulsed with either Mart
(1.0µg/mL) or hTyr368-376 (1.0µg/mL), or cells were co-cultured at a 1:1 ratio with B16
(HLA-A2ꟷ) or B16-A2 (HLA-A2+) murine melanoma cells to undergo AICD for 4 hrs. (A)
Representative histograms of Annexin V expression in Vβ12+CD8+ gated cells. (B)
Quantification of mean ± SEM of Annexin V+ amongst Vβ12+CD8+ gated cells (n=2,
*p<0.05).
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by restimulation with plate-bound anti-CD3. This polyclonal stimulation resulted in a
time-dependent increase in Annexin V staining (Fig. 7a), indicative of these T cells
undergoing AICD. In parallel, cells were stained intracellularly with a phospho-specific
fluorochrome conjugated antibody for p-p53Ser15 as well as total p53. The amount of
phosphorylated p-p53Ser15 increased in a similar time-dependent manner as observed
with Annexin V staining with a 3.72-fold increase at 2 hours of anti-CD3 restimulation as
well as an overall stabilization of total p53 expression (~2.94-fold increase) (Fig. 7b).
With its primary role as a transcription factor, nuclear accumulation is another
indication of p53 activation (576,659). To investigate the subcellular distribution of p53
upon TCR restimulation, previously activated human PBMCs were induced to undergo
AICD with polyclonal anti-CD3 restimulation and were examined using the Amnis
ImageStream imaging flow cytometer which combines flow cytometry with cellular
imaging. In addition to being stained with p53 and p-p53Ser15, PBMCs were labeled with
the nuclear marker Hoechst. Within two hours of TCR restimulation, there was nearly a
9-fold increase in the amount of p53 that co-localized with the Hoechst stained nucleus
(Fig. 8a-c). Additionally, nearly all (>97%) of the Ser15-phosphorylated p53 was detected
in the nucleus (Fig 8d), which is consistent with reports that have demonstrated Ser15
aids in nuclear accumulation and retention of p53 (577,578).
As p53 can have a transcriptionally independent role in cell death at the
mitochondria, cells were additionally stained with the mitochondrial marker
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Figure 7. p53 is phosphorylated on its Serine 15 residue upon TCR restimulation in
human PBMCs. Previously activated human PMBCs were restimulated with plate-bound
anti-CD3 (5µg/mL) for up to 120 min. Left panels are representative histograms and
contour plots of (A) Annexin V and (B) p53 and p-p53Ser15 expression after 120 min of TCR
restimulation in CD8+ gated cells. Right panels denote quantification of each indicated
maker in CD8+ cells of time course experiments with each of the four donors (grey lines)
and the mean of all donors (black line). *p<0.05, **p<0.01, and ***p<0.0001.
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MitoTracker- DeepRed. Visual and quantitative analysis revealed that virtually none of
the p53 fluorochrome conjugated antibody co-localized with MitoTracker (Fig. 8e, <0.3%).
Together these results demonstrate that p53 is activated via phosphorylation and
accumulation in the nucleus following TCR restimulation, and that p53 is likely acting in
its role as a transcription factor during the onset of AICD.

ATM is activated and required in the onset of AICD
Ataxia telangiectasia mutated (ATM), the chief kinase responsible for the
phosphorylation of p53 on Ser15, is activated via autophosphorylation on its Ser1981
residue. As such, the activation status of ATM was investigated via probing for the
expression levels of p-ATMSer1981 in previously activated human PBMCs undergoing antiCD3 restimulation. Indeed, ATM was found to be phosphorylated in a time-dependent
manner similar to the upregulation of p-p53Ser15 upon TCR restimulation with an
approximate 4.6-fold increase in the amount of p-ATMSer1981 after 2 hours of TCR
restimulation (Fig. 9a).

As other kinases could potentially be responsible for the

phosphorylation of p53, cells were additionally preincubated with the ATM inhibitors
Caffeine or KU-55933 (663,664). Both inhibitors faithfully prevented the phosphorylation
of ATM and additionally blocked the downstream phosphorylation of p53 (Fig. 9a),
suggesting that ATM is necessary for the phosphorylation of p53 on Ser15 following TCR
restimulation. Furthermore, in cells that were stained in parallel with Annexin V,
inhibition of ATM nearly completely (>99%) prevented cell death resulting from TCR
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Figure 8. p53 translocates to the nucleus upon TCR restimulation. Previously activated
human PMBCs were restimulated for 60 or 120 min with anti-CD3 and stained with
Hoechst, MitoTracker-DeepRed, p53, and p-p53Ser15. Cells were acquired on the Amnis
ImageStream with at least 10,000 events collected. Cells were gated on CD8+ cells prior
to further analysis. Representative images show localization (A) p53 and (D) p-p53Ser15
relative to Hoechst stained nucleus. (B) Representative similarity histogram of cells costained with p53 and Hoechst after TCR restimulation (C) Quantification (mean ± SEM)
of percent positive for p53/Hoechst co-localization defined as a similarity score ≥1 (E)
Same cell in ‘D’ exhibiting p53 relative to MitoTracker-DeepRed (n=2, *p<0.05).
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restimulation (Fig. 9b). Together these data suggest that ATM activity is responsible for
the phosphorylation of p53 upon TCR restimulation and is a novel upstream requisite
factor in the onset of AICD.

TCR restimulation results in the rapid upregulation of DNA damage markers
Activation of the p-ATMSer1981/p-p53Ser15 pathway is classically defined as a DNA
damage response pathway (665). However, this pathway can be activated independent
of DNA damage via oxidative stress or hypoxia (595). As oxidative stress has already been
implicated in the onset of AICD (370), the expression of two well defined markers of DNA
double-strand breaks, γH2AX and p-SMC-1 (599), were examined to determine if
activation of the p-ATMSer1981/p-p53Ser15 occurred in the presence of DNA damage.
Indeed, polyclonal anti-CD3 restimulation of previously activated human PBMCs resulted
in an increase of these DNA damage markers with a significant, 3-fold increase in
expression within 15 min of restimulation and remained elevated throughout the 2 hour
timecourse (Fig. 10). These data indicate that evidence of DNA damage parallels the onset
of ATM activation and suggest that TCR restimulation results in DNA damage and
subsequent activation of the DNA damage response pathway leading to AICD.

Detection of DNA damage response pathway activation in TIL1383I TCR transduced
therapeutic T cells
As the DNA damage response pathway further elucidates signaling pathways
involved in AICD, blocking components of that pathway, or engineering cells with
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Figure 9. ATM is activated and required for cell death following TCR restimulation in
human PBMCs. Previously activated human PBMCs were restimulated with anti-CD3
(5µg/mL) for 120 min with or without preincubation with Caffeine (10mM) or KU-55933
(100µM) 1hr prior to restimulation. After restimulation, T cells were stained in parallel
for (A) expression of p-ATMSer1981 and p-p53Ser15 or (B) Annexin V expression. Left panels
show representative contour plot or histogram of CD8+ gated cells. Right panel displays
quantification of mean ± SEM for each indicated marker in CD8+ gated cells (n=3,
*p<0.05, ns=not significant).

73

Figure 10. TCR restimulation results in the rapid upregulation of DNA damage markers
in human PBMCs. Previously activated human PBMCs were restimulated with platebound anti-CD3 (5µg/mL) for up to 120 min. Left panels are representative contour
plots of γH2AX and p-SMC-1 expression in CD8+ gated cells after 120 min of TCR
restimulation. Right panels denote quantification of time course experiments for each
indicated marker in CD8+ gated cells with each of the three donors (grey lines) and the
mean of all donors (black line). n=3, **p<0.01, and ***p<0.0001.
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enhanced DNA repair capacity, may improve therapeutic outcomes. Therefore, it was
investigated whether these observations from restimulated polyclonal PBMCs could be
applied to therapeutic T cells used in the clinic. To determine the clinical relevance of
these findings, we obtained TIL1383I transduced T cells that had been prepared for
adoptive cell transfer as part of an ongoing clinical trial (NCT01586403) from both
melanoma patients enrolled in the trial and healthy donor controls. These TIL1383I
transduced cells were co-cultured overnight with either HLA-A2+ matched MEL624 cells
or HLA-A2ꟷ MEL624-28 cells as a negative control. Previously activated by a REP,
restimulation of the TCR of TIL1383I TCR transduced human T cells by co-culture with
MEL624 cells caused the T cells to undergo cell death as evidenced by a 2.4-fold increase
in Annexin V staining compared to cells co-cultured with MEL624-28 cells (Fig. 11).
Concurrently, MEL624 co-cultured cells exhibited significant increases in p-ATMSer1981
(2.5-fold) and γH2AX (1.7-fold) expression levels (Fig. 11). Activation of the DNA damage
response pathway was also observed in the CD4+ T cell population (Fig. 12). No significant
difference was observed in Annexin V, γH2AX expression, or activation of ATM between
melanoma patients and healthy controls. Altogether, these results suggest that antigenspecific restimulation of the TCR by tumor cells likely induces DNA damage in therapeutic
T cells in the onset of AICD.
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Figure 11. DNA damage and ATM activation occurs in CD8+ TIL1383I TCR transduced
human T cells restimulated with MEL624 melanoma cells. TIL1383I TCR transduced
human T cells were co-cultured overnight at a 1:1 ratio with either MEL624-28 (HLAA2ꟷ) or MEL624 (HLA-A2+) cells. Left panels display Annexin V, γH2AX, and p-ATMSer1981
expression amongst CD34+CD8+ gated cells. Right panels denote quantification of
percent positive for each labeled marker in 3 healthy donors (grey lines) and 3
melanoma patients (black lines) in CD34+CD8+ gated cells. (n=3, **p<0.01, ***p<0.001).
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Figure 12. DNA damage and ATM activation occurs in CD4+ TIL1383I TCR transduced
human T cells restimulated with MEL624 melanoma cells. TIL1383I TCR transduced
human T cells were co-cultured overnight at a 1:1 ratio with either MEL624-28 (HLA-A2ꟷ)
or MEL624 (HLA-A2+) cells. Left panels display Annexin V, γH2AX, and p-ATMSer1981
expression amongst CD34+CD4+ gated cells. Right panels denote quantification of
percent positive for each labeled marker in 3 healthy donors (grey lines) and 3
melanoma patients (black lines) in CD34+CD8+ gated cells. (n=3, *p<0.05, ****p<0.0001).
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Accumulation of ROS is responsible for activation of the DNA damage response
pathway upon TCR restimulation
Among endogenous sources of DNA damage, oxidative stress is a predominant
assailant of DNA damage within the cell (666). ROS generated by TCR restimulation has
previously been characterized to occur within a similar timeframe as our observation of
DNA damage (≤15 min) (369). Additionally, as the accumulation of ROS has already been
implicated in the onset of AICD (370), we sought to delineate whether oxidative stress
was responsible for this observed incursion of DNA damage following TCR restimulation
or, if rather, this was the result of a separately occurring phenomenon. To address this
question, previously activated human PBMCs were preincubated with 50mM of the
antioxidant N-acetyl cysteine (NAC) 60 min prior to restimulation with anti-CD3.
Anti-CD3 restimulated human PBMCs were stained with the ROS-reactive dye
2',7'-dichlorodihydrofluorescein diacetate (DCFDA). Untreated cells exhibited an ~66.6%
increase in the DCFDA MFI when restimulated with anti-CD3 which was reduced by
~38.8% when the cells were preincubated with NAC (Fig. 13a). Moreover, pretreatment
with NAC prevented the downstream activation via phosphorylation (667) of pJNKThr183/Tyr185 , which has also been shown to be required for AICD (366) (Fig. 13b).
As previously reported, NAC treatment protects T cells from AICD following TCR
restimulation (653) as demonstrated by the failure to increase the amount of Annexin V
staining upon anti-CD3 restimulation (Fig. 14a). In parallel, pretreatment of cells with
NAC also reduced the onset of DNA damage marker expression and subsequent activation
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Figure 13. Pretreatment with NAC prevents TCR restimulation induced ROS
accumulation and JNK activation in human PBMCs. Previously activated human
PBMCs were pretreated with NAC (50mM) 60 min prior to restimulation with anti-CD3
(5µg/mL) for 4 hrs. Left panels are representative histograms of (A) DCFDA and (B) pJNK expression in CD8+ gated cells. Right panels display quantification (mean ± SEM) of
each indicated marker in CD8+ gated cells (n=3, *p<0.05, **p<0.01, ns=not significant).
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of the DDR pathway as exhibited by a 94%, 69%, and 81% reduction in the expression of
γH2AX, p-ATMSer1981, and p-p53Ser15 respectively (Fig. 14b-d).
Taken together, these results suggest that the accumulation of ROS, previously
defined to be a requisite factor for AICD (370), is the cause for the onset of the DNA
damage response pathway caused by TCR restimulation. Furthermore, this apparent
onset of DNA damage activates p53 via phosphorylation of its Ser15 by ATM, confirming
the likely role of p53 in the involvement of AICD demonstrated by previous inhibition and
knockout studies (Fig. 15) (556,668).

80

Figure 14. Pretreatment with NAC prevents the induction of γH2AX and activation of
the DDR pathway upon TCR restimulation in human PBMCs. Previously activated
human PBMCs were pretreated with 50mM NAC 60 min prior to restimulation with antiCD3 (5µg/mL) for 4 hrs. Left panels are representative histograms of (A) Annexin V, (B)
γH2AX, (C) p-ATMSer1981, and (D) p-p53Ser15 expression in CD8+ gated cells. Right panels
display quantification of mean ± SEM (n=3, *p<0.05, **p<0.01).
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Figure 15. Signaling schematic of DDR pathway activation in AICD. TCR restimulation
results in the activation of JNK and accumulation of ROS [Fig. 13 and (366,369,370)].
The accumulation of ROS results in the activation/phosphorylation of ATM (Fig. 9) and
the downstream phosphorylation of γH2AX (Fig. 10), which is indicative of DNA damage
within the cell. Downstream of ATM, p53 is phosphorylated on Ser15 (Figs 7,9) which
can be blocked by the ATM inhibitors Caffeine or KU55933, which also inhibits AICD
(Fig. 9). Upstream, neutralization of ROS accumulation by pre-treatment with the
antioxidant NAC (Fig. 13) blocks ATM activation and subsequent phosphorylation of
γH2AX and p53 protecting the T cells from death following TCR restimulation (Fig. 14).
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CHAPTER 3 – CULTURING T CELLS IN N-ACETYL CYSTEINE IMPROVES THEIR ANTITUMOR FUNCTIONALITY

Introduction
As acute treatment of T cells with NAC protected them from the apparent onset
of DNA damage and the onset of AICD, we postulated that enhancing the antioxidant
capacity of therapeutic T cells used in the clinic with NAC would likely enhance the
durability of T cells to persist and to control tumor once transferred in vivo. NAC has been
commonly used in the clinic for a multitude of diseases and conditions for many decades
and, even at very high doses, has demonstrated a consistent and well-regarded safety
profile (669). However, direct administration of NAC to patients undergoing ACT may not
effectively enhance therapy as NAC has a considerably short half-life in the plasma (477).
Moreover, protection afforded to T cells by NAC may also confer protection to tumor cells
in parallel, as NAC administration has been shown to increase tumor burden and
metastasis in murine models (670,671). However, NAC supplementation does enhance
the antioxidant capacity of T cells (653), which led us to hypothesize that culturing T cells
in NAC prior to adoptive transfer would make them more resistant to the downstream
occurrence of DNA damage and also impede the onset of AICD. Moreover, to what extent
making T cells resistant to AICD through NAC supplementation would improve their
therapeutic efficacy once transferred in vivo was examined in murine melanoma/self
antigen-specific T cells, both from the native bearing transgenic Pmel-1 model and from
T cells engineered with a TRP-1 specific TCR, both cultured in NAC prior to adoptive
transfer into B16-F10 melanoma challenged mice. Additionally, human TIL1383I TCR
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transduced cells, though not able to persist in a xenograft model, demonstrated
enhanced in vitro cytolytic ability after rapid expansion in NAC.

Culturing Pmel-1 murine T cells in NAC enhances antioxidant capacity and diminishes
their susceptibility to γH2AX induction and AICD
We used the Pmel-1 transgenic mouse as our first model, which has been a wellestablished model to demonstrate improvements in the efficacy of ACT therapy, notably
in that T cells from the Pmel-1 transgenic mouse recognize the “self” melanoma
associated antigen gp10025-33 in the poorly immunogenic B16 melanoma tumor cell (323).
Harvested splenocytes from Pmel-1 mice were activated with gp10025-33 peptide and IL-2
and then were cultured with or without the presence of NAC (10mM) added to the culture
medium for 6 days. Prior to use in adoptive transfer, the effect of NAC supplementation
was characterized on these in vitro cultured cells. Indeed, Pmel-1 T cells cultured in NAC
demonstrated an enhancement in antioxidant capacity as indicated by an increase in
surface thiols as exhibited by the thiol-reactive maleimide dye (Fig. 16). Conversely, there
was a decrease in the expression of the oxidative stress dye DCFDA (Fig. 16). Moreover,
NAC cultured T cells exhibited a decrease in DNA damage as denoted by reduced levels of
γH2AX when T cells were restimulated with gp10025-33 pulsed irradiated splenocytes,
which was consistent with these cells also being more resistant to AICD (Fig. 17).
Together, these results affirm that culturing cells in NAC confers an increase in antioxidant
capacity which subsequently makes cells more resistant to TCR restimulation induced
DNA damage and AICD.
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Figure 16. Pmel-1 T cells cultured in NAC exhibit enhanced antioxidant capacity.
Representative histograms (n=2) of Vβ13+CD8+ gated Pmel-1 splenocytes which were
activated with gp10025-33 peptide and cultured for 6 days ± 10mM NAC. Cells were
stained with the surface thiol reactive C2Maleimide dye (left panel) or the oxidative
stress indicating DCFDA dye (right panel).
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Figure 17. Pmel-1 T cells cultured in NAC are more resistant to DNA damage and AICD
upon TCR restimulation. Pmel-1 splenocytes which were activated with gp10025-33
peptide and cultured ± 10mM NAC for 6 days were then co-cultured overnight at a 1:1
ration with irradiated splenocytes pulsed with gp10025-33 peptide (1µg/mL). (A)
Representative contour plots denoting γH2AX expression of Vβ13+CD8+ gated cells
restimulated with gp10025-33 peptide (B) Quantification (mean ± SEM) of percent
Annexin V positive cells amongst Vβ13+CD8+ gated cells (n=2, *p<0.05).
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Pmel-1 murine T cells cultured in NAC demonstrate enhanced in vivo persistence after
adoptive transfer

To determine if increased resistance to DNA damage and AICD conferred an
improvement in in vivo tumor control, these Pmel-1 T cells, which had been cultured with
or without NAC (10mM) for 6 days, were adoptively transferred via retro-orbital infusion
into mice challenged with a subcutaneous injection of B16-F10 (3x105) murine melanoma
cells 6 days prior to transfer. Mice additionally received a 5 Gy dose of whole-body
irradiation the day before adoptive transfer in order to parallel patient lymphodepletion
practiced in the clinic. To monitor the persistence of transferred cells, blood draws were
taken from the tail veins of recipient mice 5 and 12 days after transfer which
demonstrated that there was a significant enhancement in the percentage of Vβ13 +CD8+
Pmel-1 T cells in the blood of mice which had received NAC cultured Pmel-1 T cells
compared to control cultured cells (Fig. 18a). Similarly, there was a 2.2-fold increase in
the percentage of Vβ13+CD8+ cells in the spleens of recipient mice receiving NAC cultured
T cells (Fig. 18b). Strikingly, in mice receiving Pmel-1 T cells cultured in NAC, close to 40%
of T cells within the tumor were Vβ13+CD8+ positive, whereas effector T cells in the
tumors of mice receiving Pmel-1 T cells cultured in the absence of NAC were scarcely
detectable (~1.2%, Fig. 18c). Together, these results demonstrate that Pmel-1 T cells
cultured in NAC, which are resistant to AICD in vitro, exhibit enhanced persistence once
they are transferred in vivo into a tumor challenged host.

87

Figure 18. Pmel-1 T cells cultured in NAC exhibit enhanced persistence once
transferred in vivo. C57BL/6 wild type mice were subcutaneously injected with 3x106
B16-F10 murine melanoma cells. After 6 days of tumor establishment, mice were
irradiated (5Gy) and treated with 2x106 Pmel-1 T cells which had been cultured ± NAC
(10mM) for 6 days and reactivated with gp10025-33 peptide (1µg/mL) overnight prior to
transfer. (A) Blood was collected from the tail vein of recipient mice on Days 5 and 12
post-transfer. Displayed is the percent of Vβ13+CD8+ cells of CD3+ gated cells for each
individual mouse. Bars in graph represent the quantification of mean ± SEM (B, C)
Spleens and tumors were harvested from a subset of mice 6 days after adoptive transfer
and processed into single-cell suspensions. Displayed is the percent of Vβ13+CD8+ cells
of CD3+ gated cells harvested from (B) the spleen or (C) the tumor for each individual
mouse. Bars in graph represent the quantification of mean ± SEM (*p<0.05, **p<0.01,
***p<0.001, ****p<0.0001).

88

Pmel-1 murine T cells cultured in NAC maintain resistance to DNA damage and AICD
upon ex vivo restimulation

Recovered splenocytes and TILs were stimulated ex vivo with gp10025-33 peptide
to determine susceptibility to DNA damage and cell death.

Because insufficient

Vβ13+CD8+ cells were recovered from tumors of mice that received control cells, we
compared Pmel-1 T cells isolated from tumors of mice receiving NAC treated cells to their
corresponding splenocytes. Cells which were cultured in NAC retained their resistance to
DNA damage even after adoptive transfer as evidenced by the amount of γH2AX+ cells
recovered from the spleen being approximately half that of controlled cultured cells (Fig.
19a). Moreover, levels of γH2AX in NAC cultured cells which had trafficked to the tumor
microenvironment, were comparable to adoptively transferred cells isolated from spleens
(Fig. 19a). Consistent with a decrease in DNA damage susceptibility, cells cultured in NAC
prior to adoptive transfer were less susceptible to AICD upon gp100 25-33 peptide
stimulation. Restimulation of T cells isolated from either the spleen or tumor with
gp10025-33 peptide shows that a majority of Pmel-1 effector T cells become Annexin V
positive and that ex vivo culture in NAC prior to adoptive transfer resulted in a significant
decrease in Annexin V expression among cells that had trafficked to the spleen or the
tumor (Fig. 19b). In addition, we found that granzyme B expression inversely correlated
with Annexin V staining and that the strongest expression was observed on Vβ13 +CD8+
NAC expanded cells that had trafficked to the tumor (Fig. 19c). Together, these results
demonstrate that the protection against DNA damage and AICD conferred to Pmel-1 T
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cells by in vitro culture is retained once cells are removed from NAC and transferred in
vivo.

Pmel-1 murine T cells cultured in NAC demonstrate enhanced tumor control and
improved survival status to recipient mice
To determine whether resistance to DNA damage and AICD translated into a
reduction in the tumor burden of recipient mice, twice weekly tumor measurements as
well as the overall survival were monitored. As expected, Pmel-1 T cells are capable of
significantly delaying tumor growth compared to mice receiving no cells (Fig. 20a,
p=0.0025), although under the conditions we used, this did not translate into a significant
survival benefit (Fig. 20b). In contrast, transfer of Pmel-1 T cells that had been cultured
in NAC resulted in highly significant delays in tumor growth compared to mice receiving
no cells (p<0.0001) and to mice receiving Pmel-1 T cells cultured in the absence of NAC
(p<0.0001). Expansion of cells in NAC also significantly increased median survival time
compared to mice receiving no cells (p=0.0004) or those receiving Pmel-1 T cells (Fig. 20b,
p=0.0002). Together these results suggest that expanding therapeutic T cells in the
presence of NAC prior to adoptive transfer, can result in long-lasting benefits following
transfer that enhance persistence, tumor control, and survival.
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Figure 19. Pmel-1 T cells cultured in NAC maintain resistance to AICD and have
enhanced expression of the cytotoxic effector molecule granzyme B after adoptive
transfer. C57BL/6 wild type mice were subcutaneously injected with 3x106 B16-F10
murine melanoma cells. After 6 days of tumor establishment, mice were irradiated
(5Gy) and treated with 2x106 Pmel-1 T cells which had been cultured ± NAC (10mM) for
6 days and reactivated with gp10025-33 peptide (1µg/mL) overnight prior to transfer.
Splenocytes and TILs harvested from mice 6 days after transfer were stimulated
overnight by co-culture at a 1:1 ratio with irradiated splenocytes pulsed with gp10025-33
peptide and then assayed for their expression of (A) γH2AX, (B) Annexin V, or (C)
granzyme B. Displayed is percent positive of each indicated marker amongst Vβ13+CD8+
gated cells for each individual mouse. Bars in graph represent the quantification of
mean ± SEM (*p<0.05, **p<0.01, ns=not significant).
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Figure 20. Pmel-1 T cells cultured in NAC demonstrate improved control of tumor
burden and survivability of recipient mice. C57BL/6 wild type mice were
subcutaneously injected with 3x106 B16-F10 murine melanoma cells. After 6 days of
tumor establishment, mice were irradiated (5Gy) and treated with 2x10 6 Pmel-1 T cells
which had been cultured ± NAC (10mM) for 6 days and reactivated with gp10025-33
peptide (1µg/mL) overnight prior to transfer. (A) Tumor growth and (B) survival was
determined for up to 35 days after adoptive transfer in untreated mice (n=8), Pmel-1 T
cell treated mice (n=10), and mice receiving NAC treated Pmel-1 T cells (n=12)
(**p<0.01, ***p<0.001, ****p<0.0001).
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TIL1383I TCR transduced human T cells expanded in NAC demonstrate an enhanced
antioxidant capacity, resistance to AICD, and superior anti-melanoma in vitro
cytotoxicity

The improvement in cell persistence, tumor control, and survival of recipient mice
conferred to Pmel-1 T cells by adding NAC to the expansion culture prior to adoptive
transfer prompted us to investigate whether NAC would be a benefit to therapeutic
TIL1383I TCR transduced human T cells. Autologous PBMCs derived from melanoma
patients and healthy donor controls were activated and transduced with the TIL1383I
TCR.

Following transduction, NAC (2mM) was added to the culture medium and

maintained through the rapid expansion of the cells (Fig. 21a). Though some reports have
suggested NAC can enhance the proliferation of T cells (654), there was not any significant
difference in the yield between cells that were expanded with or without the presence of
NAC suggesting that NAC did not enhance the proliferation of T cells at this concentration
(Fig. 21b).

However, NAC did enhance the antioxidant capacity of TIL1383I TCR

transduced human T cells. NAC REPed T cells exhibited an increased expression of surface
thiols denoted by the C2Maleimide dye (Fig. 22a). Conversely, TIL1383I transduced cells
REPed in the presence of NAC demonstrate less evidence of oxidative stress via a decrease
DCFDA staining expression (Fig. 22b). Moreover, consistent with oxidative stress being
upstream of DNA damage, NAC REPed cells were less susceptible to upregulation of
γH2AX than their control cultured counterparts when stimulated with MEL624 melanoma
cells (Fig. 22c).
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Figure 21. Production of NAC cultured TIL1383I TCR transduced human T cells. (A)
PBMCs were activated for 2 days with soluble anti-CD3 and then transduced with the
TIL1383I TCR. The day after transduction, NAC (2mM) was added to the culture medium
after which cells were then enriched based on CD34+ expression and subject to a rapid
expansion protocol whereby 1x106 CD34+ cells are co-cultured with 2x108 irradiated
feeder cells supplemented with 30ng/mL anti-CD3 for 10 days with media
replenishment at Day 5. (B) Cell counts following rapid expansion of each individual
donor. Bars in graph represent the quantification of mean ± SEM (n=6, ns=not
significant).
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Figure 22. TIL1383I TCR transduced human T cells REPed in NAC have improved
antioxidant capacity and resistance to MEL624 induced DNA damage. TIL1383I
transduced human T cells rapidly expanded for 10 days (± 2mM NAC) were stained with
(A) C2Maleimide for detection of surface thiols and (B) DCFDA for detection of oxidative
stress. (C) TIL1383I transduced cells were also co-cultured overnight with either MEL624
(HLA-A2+) or MEL624-28 (HLA-A2ꟷ) cells at a 1:1 ratio and then stained intracellularly
for detection of γH2AX. Left panels display representative histogram overlays in
CD34+CD8+ gated cells. Right panels display quantification (mean ± SEM) of each
indicated marker in CD34+CD8+ cells (n=6, *p<0.05, ****p<0.0001).
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As such, we investigated whether this improvement in antioxidant capacity and
resistance to DNA damage would improve the functional ability of NAC REPed cells to kill
melanoma tumor cells. TIL1383I TCR transduced human T cells which were rapidly
expanded with or without the addition of NAC (2mM) were subsequently washed from
the presence of NAC and co-cultured overnight with HLA-A2 matching MEL624 cells and
HLA-A2-negative MEL624-28 cells. MEL624 and MEL624-28 cells were labeled with
carboxyfluorescein succinimidyl ester (CFSE) at different concentrations which allows for
simultaneous gating of both melanoma cell types using MEL624-28 as an internal assay
control (Fig. 23a). After overnight culture, cells were stained with Annexin V and 7AAD
and analyzed via flow cytometry. Utilizing the differential CFSE staining, MEL624 and
MEL624-28 were gated on their respective CFSE concentrations. MEL624 gated cells
which were co-cultured with TIL1383I TCR transduced cells REPed in NAC demonstrated
a consistent increase in the percentage of Annexin V and 7AAD double positive cells
compared to MEL624 cells co-cultured with control REPed cells (Fig. 23a-b). Conversely,
the TIL1383I TCR transduced human T cells themselves which were cultured in NAC
exhibited increased resistance to cell death induced by tumor cells compared to control
REPed counterparts (Fig. 23c). Together these data demonstrate that rapidly expanding
TIL1383I TCR transduced human T cells in NAC enhances their ability to kill MEL624
melanoma cells while in parallel being more resistant to cell death themselves. We
further investigated whether addition of NAC to the rapid expansion of TIL1383I TCR
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Figure 23. TIL1383I TCR transduced human T cells rapidly expanded in NAC exhibit
enhanced anti-melanoma in vitro cytotoxicity. 2x104 each MEL624 (HLA-A2+) and
MEL624-28 (HLA-A2ꟷ) cells were co-cultured overnight with TIL1383I transduced
human T cells (REPed with or without 2mM NAC) plated at increasing Effector:Target
ratios. (A) Melanoma cells were gated based on being labeled with CFSE at
differentiating concentrations. MEL624-28 cells were labeled with CFSE at 0.01 µM and
gated as the “CFSE-Lo” population. MEL624 cells were labeled with CFSE at 0.1 µM and
gated as the “CFSE-Hi” population. (B) Representative flow plot of Annexin V vs 7AAD
expression at a 2:1 Effector:Target ratio. (C) Quantification (mean ± SEM) of Annexin
V/7AAD double-positive cells at expanded Effector:Target ratios. (D) Quantification
(mean ± SEM) of Annexin V MFI in TIL1383I transduced cells gated as CFSEnegCD34+CD8+
(n=5, *p<0.05, **p<0.01).
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transduced human T cells modulated their functional capacity. In our model system, NAC
supplementation did not demonstrate any obvious enhancement in the functional
capacity of cells to secrete IFNγ as there was no significant difference between NAC REPed
and control cells (Fig. 24a). Moreover, the surface expression of CD107a, a marker
indicative of the degranulation of cytotoxic effector molecules (672), was also unaltered
between T cells REPed in NAC and control cultured cells (Fig. 24b). Additionally, there
was no significant difference (p=0.62) between NAC and control REPed cells as to the
expression of the cytotoxic molecule perforin (Fig. 25a). However, in contrast, there was
a significant increase of cells positive for the cytotoxic molecule granyzme B amongst NAC
cultured cells (Fig. 25b).
As these in vitro results suggested that NAC conferred an enhanced antimelanoma cytolytic ability to human cells similar to what was observed in vivo with the
murine Pmel-1 model, we sought out to investigate if culturing TIL1383I TCR transduced
cells in NAC would improve their anti-melanoma functionality in a preclinical model. To
do so, TIL1383I TCR transduced human T cells cultured with or without NAC were
adoptively transferred into MEL624 challenged NSG mice. However, transferred TIL1383I
TCR human transduced T cells did not persist once transferred as there was no detectable
observance of CD3+CD34+ T cells in the spleens of any mice receiving cells above the “no
cell” controls (Fig. 26). As such, there was no differentiation in tumor burden control
amongst the treatment groups (Fig. 26). Unfortunately, the failure of transferred cells to
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Figure 24. Effect of NAC supplementation during REP on the functional capacity of
TIL1383I TCR transduced human T cells. TIL1383I TCR transduced human T cells which
were rapidly expanded for 10 days (± 2mM NAC) were co-cultured overnight with
MEL624 (HLA-A2+) or MEL624-28 (HLA-A2ꟷ) cells and then (A) stained intracellularly for
IFNγ expression (B) or preloaded with a CD107a fluorochrome conjugated antibody in
order to assess stimulation induced surface expression. Left panels are representative
contour plots of indicated marker in CD34+CD8+ gated cells. Right panels are
quantification of percent positive for each indicated marker amongst CD34 +CD8+ gated
cells. Bars denote mean ± SEM (n=6).
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Figure 25. Effect of NAC supplementation during REP on the functional capacity of
TIL1383I TCR transduced human T cells. TIL1383I TCR transduced human T cells which
were rapidly expanded for 10 days (± 2mM NAC) were stained for intracellular
expression of (A) perforin or (B) granzyme B. Top panels are representative histograms
comparing NAC and control cultured cells to FMO controls in CD34+CD8+ gated cells.
Bottom panels are quantification of percent positive for each indicated marker amongst
CD34+CD8+ gated cells. Bars denote mean ± SEM (n=6, *p<0.05).
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Figure 26. Lack of persistence of TIL1383I TCR transduced human T cells in NSG
xenograft model. 10x106 CD34+ enriched TIL1383I TCR transduced cells were
adoptively transferred into NSG mice challenged with MEL624 tumors (5x106 cells). At
56 days post transfer, the experiment was terminated and mice were sacrificed. (A)
Representative contour plots denoting CD3+ and CD34+ expression of spleens
harvested from mice. (B) Quantification of percent CD3 +CD34+ double-positive cells
from spleen represented in ‘A’ for each individual mouse. (C) Tumor growth of mice
receiving either no treatment, TIL1383I TCR transduced cells, or TIL1383I TCR
transduced cells expanded in 2mM NAC (n=7 per treatment group).
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persist in this model did not allow for any discernment as to whether TIL1383I TCR
transduced human T cells would demonstrate enhanced in vivo functionality from being
expanded in the presence of NAC, and thus, a humanized model for TIL1383I TCR
transduced cells merits further optimization.

Effect of NAC supplementation on TCR transduced T cells in a murine model
As we were unable to investigate the effect of NAC on in vivo tumor control using
TIL1383I TCR transduced human T cells in a NSG xenograft model, we alternatively used
a completely murine model whereby splenocytes from C57BL/6 wild type mice were
transduced with the TRP-1 TCR, which recognizes the melanoma associated antigen TRP1 (324,326). After activation and transduction, these cells were expanded with or
without NAC supplementation and adoptively transferred, into lymphodepleted, B16-F10
challenged C57BL/6 wild type mice. As observed in the Pmel-1 model, the addition of
NAC (10mM) to the culture of TRP-1 splenocytes enhanced the expression of surface
thiols while concurrently diminishing the susceptibly of cells to TRP-1 peptide induced
DNA damage and AICD as indicated by a reduction in expression of γH2AX and Annexin V
respectively (Fig. 27). However, in contrast to the Pmel-1 model, there was no significant
increase in the percentage of adoptively transferred NAC cultured T cells detected in the
spleens or tumors of mice sacrificed for biodistribution analysis (Fig. 28a,b). However,
TRP-1 TCR transduced cells cultured in NAC did demonstrate an enhancement in their
functional capacity when stimulated ex vivo with peptide when compared to control
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Figure 27. In vitro characterization of TRP-1 TCR transduced murine T cells cultured in
NAC. (A) Representative histogram overlay of C2maleimide dye expression in
Vβ14+CD8+ gated TRP-1 TCR transduced murine T cells cultured for 6 days ± NAC
(10mM). (B) Representative histogram overlay of γH2AX expression of Vβ14+CD8+
gated cells cultured ± NAC (10mM) after overnight restimulation with co-culture at a
1:1 ratio with irradiated splenocytes pulsed with TRP-1 peptide (4µg/mL). (C) TRP-1
cells cultured ± NAC (10mM) were restimulated or not by co-culture at a 1:1 ratio with
irradiated splenocytes pulsed with TRP-1 peptide (4µg/mL). Displayed is representative
histogram overlays demonstrating change in Annexin V expression in Vβ14+CD8+ upon
TRP-1 restimulation for cells cultured with or without NAC (all panels are representative
of n=2).
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cultured cells. Similar to the Pmel-1 model, there was an enhancement in the expression
of granzyme B (Fig. 28c), and moreover, TRP-1 TCR transduced cells cultured in NAC
demonstrated an increase in the amount of cells positive for IFNγ cytokine expression as
well as an increase in the proliferation marker Ki-67 (Fig. 28d,e). Additionally, TRP-1 TCR
transduced cells cultured in NAC prior to adoptive transfer were less susceptible to
peptide induced DNA damage and cell death in both the spleens and tumors of recipient
mice (Fig. 29a,b). The amount of Annexin V+ T cells was reduced by nearly half in Vβ14+
cells harvested from the spleens of mice receiving NAC cultured cells, and in the tumors
of mice receiving control cultured cells, nearly 60% of Vβ14+ cells were Annexin V+ which
was reduced 5.1-fold amongst the cells cultured in NAC prior to adoptive transfer (Fig.
29a). Similar to observations in the Pmel model, mice receiving TRP-1 transduced cells
that were cultured in NAC prior to adoptive transfer exhibited a significant delay in tumor
growth compared to control cells (p=0.025), which themselves demonstrated a significant
enhancement in outcome compared to untreated mice (Fig. 29c, p<0.0001). Moreover,
the transfer of TRP-1 TCR transduced cells significantly extended the median survival time
compared to untreated mice (p=0.0289), with TRP-1 cells previously cultured in NAC
exhibiting an even further significant extension in survival compared to control cultured
cells (Fig. 29d, p=0.0243).

Together these results demonstrate that, similar to

observations in native TCR bearing T cells, expanding TCR transduced cells in the presence
of NAC can enhance their antioxidant capacity leading to a durable resistance to TCR
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Figure 28. TRP-1 TCR transduced murine T cells cultured in NAC demonstrate
enhanced functional capacity after adoptive transfer. C57BL/6 wild type mice were
subcutaneously injected with 3x106 B16-F10 murine melanoma cells. After 6 days of
tumor establishment, mice were irradiated (5Gy) and treated with 2x106 TRP-1 TCR
transduced T cells which had been cultured ± NAC (10mM) for 6 days prior to transfer.
(A) Spleens and (B) tumors were harvested from recipient mice 9 days post transfer and
processed into single-cell suspensions. Displayed is the percent of Vβ14+ cells of CD3+
gated cells from each individual mouse. (C-E) Harvested splenocytes were additionally
stimulated overnight with a co-culture at a 1:1 ratio with irradiated splenocytes pulsed
with TRP-1 peptide (4µg/mL) and then stained intracellularly for the expression of (C)
granzyme B, (D) IFNγ, or (E) Ki-67. Displayed is the percent positive for each indicated
marker for each mouse in Vβ14+CD8+ gated cells (*p<0.05).
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Figure 29. TRP-1 TCR transduced murine T cells cultured in NAC are more resistant to
DNA damage and cell death while exhibiting enhancement in tumor burden control
and survivability of recipient mice. C57BL/6 wild type mice were subcutaneously
injected with 3x106 B16-F10 murine melanoma cells. After 6 days of tumor
establishment, mice were irradiated (5Gy) and treated with 2x106 TRP-1 TCR transduced
T cells which had been cultured ± NAC (10mM) for 6 days prior to transfer. (A-B)
Splenocytes and TILS harvested from mice 9 days post transfer were stimulated
overnight with co-culture at a 1:1 ration of irradiated splenocytes pulsed with TRP-1
peptide (4µg/mL) and then assayed for their expression of (A) Annexin V or (B) γH2AX.
Displayed is percent positive of each indicated marker for each individual mouse in
Vβ14+CD8+ gated cells. (C) Tumor growth and (D) survival was determined for up to 36
days after adoptive transfer in untreated mice, mice receiving TRP-1 TCR transduced
cells, and mice receiving TRP-1 TCR transduced cells cultured in NAC. (*p<0.05,
**p<0.01, ****p<0.0001).
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restimulation induced DNA damage and cell death, while additionally conferring
enhanced functional capacity exhibited by increased granzyme B expression and delay in
tumor growth and morbidity. Together these results demonstrate that culturing cells in
NAC prior to co-culture with tumor cells in vitro and adoptive transfer in vivo improves
the anti-tumor cytolytic functionality of the T cells. Moreover, as the improvement in in
vivo tumor control is maintained after T cells are removed from NAC and adoptively
transferred, these data suggest that NAC supplementation to culture media imparts a
durable alteration and improvement in the phenotype of T cells.
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CHAPTER 4 – CULTURE OF TIL1383I TCR TRANSDUCED HUMAN T CELLS IN N-ACETYL
CYSTEINE ATTENUATES EXPRESSION OF EXHAUSTION ASSOCIATED RECEPTORS AND
TRANSCRIPTION FACTORS
Introduction
In Chapter Three, we observed that melanoma antigen-specific T cells expanded
in NAC maintained a DNA damage and AICD resistant phenotype multiple days after
removal from NAC and subsequent in vivo transfer both in the Pmel-1 native TCR model
as well as in murine T cells which were transduced with the TRP-1 TCR.

These

observations suggest that NAC confers a durable alteration to the phenotype of T cells
beyond transient antioxidant protection. Consistent with that premise, there have been
many reports in the literature which have demonstrated phenotypic improvements in T
cells which have been cultured in NAC. In addition to corroborating our observations that
NAC increases the antioxidant capacity of T cells, NAC has also been shown to enhance
the proliferation and cytokine production of T cells, as well as restore the functional
capacity of T cells from advanced stage cancer patients (537,539,653,654). However, the
rapid expansion of therapeutic T cells to achieve a sufficient quantity for infusion
counterproductively results in T cells that are functionally less fit for durable tumor
control. This decline in fitness is characterized by a degradation of telomeres (170), loss
of the CD28 co-stimulatory receptor (170), an increase in effector-memory T cells with a
parallel decrease in central-memory T cells (169), and an increase in the expression of
exhaustion markers such as PD-1 (170). The enhanced ability of TIL1383I TCR transduced
human T cells that were rapidly expanded in NAC to kill HLA-A2 matched MEL624 cells in
vitro (Fig. 24) suggested that NAC may protect cells from the decline in fitness caused by
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rapid expansion. As such, we sought to further interrogate how NAC may alter the
phenotype of T cells when added to the culture medium during rapid expansion.

Enhancement of cytotoxicity amongst NAC cultured TIL1383I transduced human T cells
is independent of alteration in memory phenotype or costimulatory receptors
As central memory cells (TCM) have been reported to be more efficacious in tumor
control than effector memory cells (TEM) (673), as an initial approach, we investigated
whether NAC altered the output of memory phenotype subsets of T cells at the conclusion
of a REP. TIL1383I transduced human T cells which had been subjected to a REP (±2mM
NAC) were stained with fluorochrome-conjugated antibodies against CD45RO, CD62L,
and CCR7 with TEM cells defined as CD45RO+CD62LLOCCR7LO and TCM cells as
CD45RO+CD62LHICCR7HI. Analysis of these memory markers did not reveal any major
difference in TEM/ TCM subsets between T cells expanded with or without NAC as there
was no significant difference in the expression of the central memory markers CD62L or
CCR7 relative to CD45RO (Fig. 30).
Moreover, since the expression of CD28 positively correlates with the therapeutic
efficacy of transferred cells (162), and the engagement of co-stimulatory receptors such
as CD28 and 4-1BB can protect T cells against AICD (171,351,352), we examined whether
NAC modulated the levels of these co-stimulatory receptors. As with memory markers,
there was no enhancement in the expression of the co-stimulatory receptors CD28 or 41BB (Fig. 31a-b). However, we did detect an increase in the intensity for the expression
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Figure 30. REP in NAC does not alter expression of memory markers on TIL1383I TCR
transduced human T cells. TIL1383I TCR transduced human T cells which were rapidly
expanded for 10 days ± NAC (2mM) were stained for the expression of (A) CD45RO and
CD62L or (B) CD45RO and CCR7. Left panels are representative flow plots showing the
expression of CD45RO vs CD62L or CCR7 in CD8+ or CD4+ gated cells as indicated. Right
panels show quantification of percent positive for indicated marker for each individual
donor. Bars denote mean ± SEM (n=7, ns=not significant).
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of the ICOS co-stimulatory receptor in cells that were expanded in NAC (Fig 31c).
Together, these results demonstrate that improvement of the cytotoxic function of NAC
REPed cells seems to be independent of a major alteration of memory T cells subsets or
enhancement of co-stimulatory receptors.

TIL1383I transduced human T cells rapidly expanded in the presence of NAC
demonstrated an attenuation of exhaustion markers
The rapid expansion of therapeutic T cells has been shown to enhance the
expression of the exhaustion marker PD-1 and the senescence marker CD57 on T cells
(170), both of which associate with impaired functionality (674,675). Consistent with
these previous reports, the rapid expansion of TIL1383I TCR transduced human T cells
resulted in an increase in the expression of both PD-1 and CD57 (Fig. 32). However,
supplementation with NAC impeded the upregulation of these markers culminating in a
significant decrease in the expression of PD-1 and CD57 when NAC REPed T cells were
compared to control cultured cells. (Fig. 32).
As exhaustion in T cells has been attributed to the relative expression levels of the
transcription factors T-bet and EOMES, with exhausted cells exhibiting a T-betLoEomesHi
phenotype (618), TIL1383I TCR transduced human T cells were further interrogated to
determine if NAC modulated the expression of these transcription factors. There was not
a significant difference in the expression of T-bet between cells which were REPed in NAC
and control cells (Fig. 33a). However, in contrast, there was a significant decrease in the

111

Figure 31. Effect of NAC REP supplementation on expression of co-stimulatory
markers on TIL1383I TCR transduced human T cells. TIL1383I TCR transduced human
T cells were rapidly expanded for 10 days (±2mM NAC) and were surface stained for the
expression of (A) CD28, (B) 4-1BB, or (C) ICOS. Left panels display representative
histogram overlay of NAC and controlled REPed cells compared to FMO control in CD8+
gated cells. Right panel display percent positive or MFI for each individual donor in
either CD8+ or CD4+ gated cell as indicated. Bars denote mean ± SEM (n=7, *p<0.05,
ns=not significant).
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Figure 32. TIL1383I TCR transduced human T cells rapidly expanded in NAC display
reduced expression of markers of exhaustion and senescence. TIL1383I TCR
transduced human T cells which were rapidly expanded for 10 days (± 2mM NAC) and
were surface stained for the expression of (A) PD-1 or (B) CD57. Left panels display
quantification of mean ± SEM of the percent positive in CD8+ gated cells for each
indicated marker on analysis performed on samples cryopreserved at indicated timepoints throughout the REP. Right panels display representative contour plots of each
indicated marker (vs side-scatter) in Post-REP samples in CD8+ or CD4+ gated cells as
indicated. (n=7, *p<0.05).
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percentage of cells which were EOMES+ amongst NAC REPed cells compared to control
cells (Fig. 33b). Together these results demonstrate that addition of NAC to the culture
medium of rapidly expanded T cells results in the cells being less exhausted which is likely
regulated, in part, by a reduction in the activity of the exhaustion associated transcription
factor EOMES.

TIL1383I TCR transduced human T cells rapidly expanded in NAC have reduced
expression of the transcription factor Foxo1
Upstream of EOMES, the transcription factor Foxo1 has been implicated in
modulation of the exhausted T cell phenotype, and specifically involved in PD-1
expression, in part through the promotion of EOMES (631). Additionally, Foxo1 represses
granzyme B expression (648) which was observed to increase in NAC REPed cells (Fig.
25b). Therefore, we predicted that NAC likely restrains the expression of Foxo1 and
interrogated TIL1383I TCR transduced human T cells cultured in NAC for Foxo1
expression. Indeed, cells cultured in NAC had a nearly 2.7-fold decrease in the expression
of the Foxo1 transcription factor in comparison to control cultured cells (Fig. 34).
Foxo1 is inactivated via phosphorylation which both promotes its sequestration
outside of the nucleus which restricts its activity as a transcription factor and ultimately
aids in facilitating the ubiquitination and subsequent proteasomal degradation of Foxo1
(640,676). Therefore, to determine if NAC influenced the phosphorylation status of
Foxo1, T cells were acutely treated with NAC for 60 min and then stained intracellularly
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Figure 33. TIL1383I TCR transduced human T cells rapidly expanded in NAC display
reduced expression of the transcription factor EOMES. TIL1383I TCR transduced
human T cells were rapidly expanded for 10 days (± 2mM NAC) and were stained
intracellularly for the expression of (A) T-bet or (B) EOMES. Left panels display
representative histogram overlays of each indicated marker comparing NAC REPed and
control cells to FMO control in CD8+ gated cells. Right panels display percent positive
or MFI for each individual donor in CD8+ and CD4+ gated cells as indicated. Bars denote
mean ± SEM (n=7, *p<0.05, ns=not significant).
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Figure 34. TIL1383I TCR transduced human T cells cultured in NAC have reduced
expression of the Foxo1 transcription factor. TIL1383I TCR transduced human T cells
were rapidly expanded for 10 days (± 2mM NAC) and were stained intracellularly for the
expression of Foxo1. Left panels display representative histogram overlays of each
indicated marker comparing NAC REPed and control cells to FMO control in CD8+ gated
cells. Right panel displays percent positive Foxo1 for each individual donor in CD8+ and
CD4+ gated cells as indicated. Bars denote mean ± SEM (n=5, **p<0.01, ***p<0.001).
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for expression of p-Foxo1.

Indeed, treatment of T cells with NAC induced the

phosphorylation of Foxo1 with an approximately 20% increase in the MFI intensity of pFoxo1 expression (Fig. 35a).

Consistent with the role of phosphorylation in the

degradation of Foxo1, there was also an observable rapid decline in the overall expression
of total Foxo1 when cells were acutely treated with NAC (Fig. 35b).
We then investigated whether NAC had an effect of upstream factors established
to be responsible for the phosphorylation of Foxo1. In particular, the activity of both
mTOR and AKT have been implicated in the phosphorylation and subsequent repression
of Foxo1 (648). Consistently, TIL1383I TCR transduced cells which have been REPed in
NAC demonstrated an approximate 2.14-fold increase in the expression of phospho-S6
(Fig. 36a), a canonical marker of mTOR activity (677). Moreover, acute treatment of T
cells with NAC enhanced the phosphorylation of AKT (Fig. 36b). Together, these results
demonstrate that treatment of T cells with NAC represses the Foxo1 transcription factor
via phosphorylation by upstream activation of mTOR and AKT pathways.
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Figure 35. Acute treatment of T cells with NAC rapidly phosphorylates and attenuates
the expression of Foxo1. Human TIL1383I T cells were acutely treated with NAC
(25mM) for 60 min and then stained intracellularly for the expression of (A) p-Foxo1 and
(B) total Foxo1. Left panels display representative histogram overlays of each indicated
marker comparing NAC REPed and control cells to FMO control in CD8+ gated cells. Right
panels display MFI or percent positive of the indicated marker for each individual donor
in CD8+ and CD4+ gated cells as indicated. Bars denote mean ± SEM (n=5, **p<0.01,
***p<0.001).
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Figure 36. T cells cultured in NAC exhibit activation of mTOR and AKT pathways. (A)
TIL1383I TCR transduced human T cells were rapidly expanded for 10 days (± 2mM NAC)
and were intracellularly stained for the expression of pS6. (B) TIL1383I T cells were
acutely treated with NAC (25mM) for 60min. Bars denote mean ± SEM (n=6, *p<0.05).
Left panels display representative histogram overlays of each indicated marker
comparing NAC treated and control cells to FMO control in CD8+ gated cells. Right
panels display MFI or percent positive of the indicated marker for each individual donor
in CD8+ or CD4+ gated cells as indicated. Bars denote mean ± SEM (n=5-6, *p<0.05,
***p<0.001).
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CHAPTER 5 – DISCUSSION AND FUTURE DIRECTIONS

The adoptive cell transfer (ACT) of melanoma-specific TILs has generated curative
responses in upwards of 40% of patients receiving this experimental therapy (219) which
represents a significant improvement compared to the five-year survival rate of only
15.2% associated with standard-of-care regimens (189).

Efficacy of treatment is

independent of an individual patient’s tumor or metastatic burden (155), but is highly
dependent on the quality of the infused cell. Therapeutic efficacy of transferred cells is
ultimately constrained by the durability of the cell to persist and to maintain anti-tumor
functionality (166).
As a necessary mechanism of immune peripheral tolerance, activated T cells are
programmed to undergo activation-induced cell death (AICD) upon repetitive stimulation
of the T cell receptor (TCR). While indispensable for the prevention of autoimmune
disorders, AICD can potentially be problematic in the clinical manipulation of T cells for
ACT. As such, younger, less differentiated T cells, which are less susceptible to AICD, have
consistently demonstrated superiority at in vivo tumor control (156,160,678).

For

instance, central memory cells, which have been well appreciated in the literature to be
more efficacious in ACT based tumor control than effector memory cells (673), are less
susceptible to AICD (653). Counterproductively, however, the rapid expansion protocol,
necessary to generate a sufficient quantity of T cells for infusion, pushes the cells more
towards a terminally differentiated effector phenotype (170), which ultimately makes
them more susceptible to AICD (171). As such, novel manipulations of ex vivo culture are
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needed to improve the phenotype of cells generated for ACT towards being more
resistant to AICD.
AICD has previously been defined to be dependent on the accumulation of ROS
and activation of JNK (366,370), and was, contemporaneously to this thesis project,
reported to be inhibited by the p53 inhibitor pifithrin-µ (556). However, pifithrin-µ has
been separately characterized as an inhibitor of the protein chaperone HSP70 inducing
cell death by dysregulated protein aggregation (657). As such, data generated with
pifithrin-µ cannot be directly attributed to p53. The use of the p53-knockout mouse in
this thesis confirms that the presence of p53 is necessary for optimal AICD induced by TCR
restimulation (Fig. 5). Furthermore, the relevance of p53 in AICD was demonstrated for
both native and transduced TCRs with either p53 knockout mice that were crossbred with
the TIL1383I TCR expressing h3T mouse, or with p53 knockout splenocytes that were
transduced with the TIL1383I TCR (Fig. 6). However, the protection observed by p53
ablation was only partial suggesting that other pathways are concurrently activated
during AICD, or potentially, some reports have suggested that p73, a paralogue of p53,
can compensate for p53 in p53-null cell lines (679). Additional studies using RNA
interference for the transient knockdown of p53 in wild type cells should be performed
to distinguish protection from AICD from possible compensatory mechanisms in knockout
cells.
Beyond demonstrating the requirement of p53 for the optimal onset of AICD, data
from this thesis demonstrate that p53 is indeed activated upon TCR restimulation
concurrent with the onset of cell death. TCR restimulation induces the phosphorylation
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of p53 on Serine-15 (Fig. 7) which allows it to dissociate from the proteasomal
degradation induced by its chief negative regulator HDM2 (572,573). Serine 15 is also
located within a nuclear export signal motif on p53 which is deactivated upon Ser15
phosphorylation (578) facilitating the accumulation of p53 in the nucleus. Such nuclear
accumulation, another hallmark of p53 activation (659), was also demonstrated by the
co-localization of p53 with the Hoechst stained nucleus visualized on the Amnis
ImageStream imaging flow cytometer (Fig. 8). Outside of the nucleus, p53 can function
at the mitochondria to promote formation of the mitochondrial outer membrane
permeabilization (569,570). However, there was no observable p53 co-localization with
the mitochondria upon TCR restimulation (Fig. 8e), indicating that p53 likely augments
AICD through its role as a transcription factor. As such, future investigations should
interrogate what p53 pro cell death gene targets (i.e. BID, BAX, AIF) are upregulated upon
TCR restimulation (575,680).
The role of p53 in AICD is consistent with the many reports demonstrating p53 to
be an emerging factor in immune system regulation beyond simply maintaining genomic
integrity. Watanabe et al. elegantly demonstrated that p53 enforces the requirement of
TCR signaling for the proliferation of T cells as p53KO T cells were unrestrained in
proliferation induced by IL-2 without antigen (582). p53 also constrains the development
of autoimmune pathologies by promoting the differentiation of T regulatory cells (Tregs)
(583,681). Additionally, the data of this thesis demonstrating an active role for p53 in
AICD makes sense of the many reports where loss of p53 expression or function
exaggerates autoimmunity and co-associates with many autoimmune conditions where
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defective AICD is also problematic, including arthritis (584–588), multiple sclerosis,
(589,590), and Crohn’s disease (591,592).
Phosphorylation of p53 on Ser15 is indicative of a p53 response to DNA damage
(665), and is moreover, required for subsequent cell death as an Alanine substitution on
Ser15 thwarts cell death induced by genotoxic stress (579). Similarly, T cells from patients
with ataxia telangiectasia, which have mutationally dysfunctional ATM, are also resistant
to cell death induced by DNA damaging insults (594). Moreover, these cells are also
resistant to phosphorylation of p53 on Ser15 (596). Consistently, data from this thesis
demonstrate that ATM is also activated during AICD and, as demonstrated using the ATM
inhibitors Caffeine and KU55933, activated p-ATMSer1981 is also necessary for the
phosphorylation of p53 on Ser15 (Fig. 9a). Additionally, cells were protected from AICD
via ATM inhibition (Fig. 9b), demonstrating ATM to be a novel requisite factor in the onset
of AICD.
Indeed, as activation of the p-ATMSer1981/p-p53Ser15 pathway, has been classically
defined as a DNA damage response pathway (665), data from this thesis demonstrate the
novel finding that TCR restimulation of activated cells likely induces damage to the DNA
as evidenced by the upregulation in active DSB repair proteins: γH2AX and p-SMC1 (Fig.
10). This incursion of DNA damage happened very rapidly (≤15min) which is consistent
with the kinetics of TCR restimulation induced oxidative stress accumulation (369). This
accumulation of oxidative stress was demonstrated to be upstream of DNA damage as
neutralization with the antioxidant N-acetyl cysteine (NAC) prevented an uptake in ROS
expression as well as the onset of DNA damage during TCR restimulation (Fig. 14).
123

The data from this thesis, which demonstrate that TCR restimulation results in the
upregulation of γH2AX and pSMC-1, indicative of DNA damage (599), is consistent with
many reports which have indicated that DNA damage is problematic for proper immune
cell function.

Immune cells from individuals with advanced age present with an

accumulation of DNA damage coupled with a diminished capacity in DNA double-strand
break repair which correlates with a decline in immune function and increased
senescence (682,683). Moreover, the accumulation of DNA damage and downregulation
of DNA repair machinery can even be observed within the conserved time-frame of in
vitro culture (684,685). Transferred T cells with eroded telomeres correlate with poor
persistence and patient responses in ACT clinical trials (161). T cells with shorter
telomeres, additionally, have higher baselines levels of γH2AX expression, a delayed DNA
repair response, and are overall more susceptible to cell death (686,687). These reports
suggest that cells with accumulated DNA damage are less fit to efficiently control tumor.
Consistent with this premise, Sukumar et al. have recently demonstrated that T cells with
less γH2AX expression are indeed superior at in vivo tumor control (688).
As the amount of DNA damage in lymphocytes has been shown to negatively
correlate with the level of intracellular glutathione (689), we were successfully able to
reduce the expression of the DNA damage marker γH2AX in Pmel-1 murine T cells when
the glutathione pro-drug NAC was added to the culture media during expansion (Fig. 17).
Affirming the role of DNA damage in the onset of AICD, these cells were also less
susceptible to AICD when restimulated with cognate gp10025-33 peptide (Fig. 17b).
Importantly, resistance to DNA damage and AICD was durable as Vβ13+ cells recovered
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from the spleens of mice receiving Pmel-1 cells expanded in NAC were more resistant to
gp10025-33 peptide induced γH2AX formation and AICD than recovered control cultured
cells (Fig. 19). These previously NAC cultured cells, which continued to demonstrate
reduced susceptibility to AICD, also exhibited increase persistence in the blood and
spleens of recipient mice as well as a strikingly 33-fold improvement in recovered Vβ13+
from the tumors of B16-F10 challenged mice (Fig. 18). Consistent with the persistence of
transferred cells being a key corollary of therapeutic success in the clinic (166), these
more durable NAC cultured cells enhanced tumor control and survival of recipient mice
(Fig. 20), which supports the central premise of this thesis that protecting T cells from
AICD may bolster their therapeutic efficacy. Moreover, enhancement of tumor burden
control and the survivability of recipient mice was observed in murine splenocytes
transduced with the TRP-1 TCR that were cultured in NAC prior to transfer (Fig. 29),
affirming that supplementation of culture media with NAC during lymphocyte expansion
to be beneficial in both native and transduced TCR models.
Similarly, adding NAC to the culture during the rapid expansion of TIL1383I TCR
transduced human T cells also attenuated susceptibility to DNA damage, alongside higher
levels of surface thiols and reduced oxidative stress (Fig. 22). Even though there was not
an adequate model to demonstrate an enhancement of in vivo tumor control by NAC (Fig.
26), these cells did consistently demonstrate themselves to be superior at in vitro antimelanoma cytotoxicity than cells cultured without the addition of NAC (Fig. 23).
As the Pmel-1 model demonstrated that functional enhancements conferred by
NAC culture were durable even after cells were removed from NAC and transferred in
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vivo, we wanted to further investigate what phenotypic alternations may occur to
therapeutic T cells cultured in NAC that would be indicative of better efficacy for ACT.
Memory cells are more resistant to cell death induced by DNA damage than naïve cells
(690) and central memory cells (TCM) exhibit enhanced levels of surface thiols and
resistance to TCR restimulation induced cell death compared to effector memory cells
(TEM) (653). Moreover, adoptive transfer of TCM cells has demonstrated a superior ability
to control tumor than TEM cells (673). These studies prompted us to investigate whether
the boosting of surface thiol levels and attenuation of DNA damage via NAC treatment
would alter the percentages of TCM/TEM subsets. However, there was no alteration in
CD62L and CCR7 expression amongst CD45RO+ cells (Fig. 30) which have been well
established to define TCM (CD45RO+CD62LHICCR7HI) and TEM (CD45RO+CD62LLOCCR7LO)
memory subsets (691).
The effect of NAC on the expression of CD28 and 4-1BB co-stimulatory receptors
was also examined. Addition of these signaling domains was one of the paramount
improvements in CAR cell technology (105,106). CD28 co-stimulation alongside TCR
restimulation can protect T cells from AICD (352), and moreover, CD28 expressing cells
are more resistant to anti-CD3 induced AICD even without CD28 ligation (692). Similarly,
ligation of 4-1BB also protects cells from AICD (171) and is being investigated in the clinic
as a potential agonist therapy (693). However, TIL1383I TCR transduced human T cells
cultured in NAC did not differ consistently in the expression of these markers compared
to control cells; though, in our panel, we did observe an increase in the intensity of the
costimulatory receptor ICOS (Fig. 31).
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The exhaustion marker PD-1 is transiently upregulated during initial T cell
activation, yet is sustained in chronically stimulated exhausted cells (609). Consistent
with previous reports (170), TIL1383I TCR transduced human T cells rapidly expanded in
our model system exhibited an increase in the exhaustion marker PD-1 as well as the
senescence marker CD57 both of which associate with T cell dysfunction (674,675).
However, the addition of NAC to the culture medium during rapid expansion significantly
thwarted the expression of these markers (Fig. 32). Beyond receptor expression, NAC
suppressed the development of an exhausted phenotype in these T cells at the
transcriptional level by repressing the exhaustion associated transcription factor EOMES
(Fig. 33). Attenuation in the development of T cell exhaustion or senescence by NAC is
consistent with the reduction in DNA damage (γH2AX+ cells) in NAC cultured cells as
γH2AX expression associates with cells exhibiting a senescent phenotype (694,695) and
corresponds to a dysfunctional response to IFN-α, IL-2, and IL-6 cytokine stimulation in
chronically stimulated T cells (696).
EOMES, which promotes the exhausted phenotype in T cells (697), has also been
reported to be downstream of the transcription factor Foxo1 as repression of Foxo1
attenuates both EOMES and PD-1 expression (631). In agreement with this role of Foxo1
in the development of the exhausted phenotype, TIL1383I TCR transduced human T cells
which were REPed in the presence of NAC additionally demonstrated reduced expression
of Foxo1 in comparison to control cultured cells (Fig. 34).
The expression of Foxo1 is regulated primarily by phosphorylation mediated by
activated Akt. Phosphorylation of Foxo1 results in cytoplasmic sequestration which
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hampers its functionality as a transcription factor, and ultimately, in the cytosol, Foxo1 is
ubiquitinated and then degraded in the proteasome (640,676). Consistently, when T cells
were acutely treated with NAC there was an upregulation in the expression in both
phosphorylated Foxo1 and phosphorylated (activated) Akt (Fig. 35-36). These data are
consistent with other reports demonstrating the phosphorylation of Akt by NAC in other
cell types such as neurons (698), cardiomyocytes (699), hepatocytes (700), and pancreatic
islet cells (701).
Foxo1 can also be repressed by mTOR as demonstrated by a report from the
Laboratory of Protul Shrikant which showed that T cells treated with the mTOR inhibitor
rapamycin had enhanced Foxo1 activity as evidenced by an increase in total Foxo1
expression alongside a decrease in phosphorylated (inactive) Foxo1 (648). Consistently
we observed the inverse, that TIL1383I TCR transduced human T cells expanded in NAC
had an increase in the expression of phospho-S6 (pS6) (Fig. 36a) indicative of enhanced
mTOR pathway activity (702), alongside a decrease in Foxo1 expression.
The restraint of Foxo1 activity by mTOR harmonizes many parallel reports in the
literature which have demonstrated that either the repression of mTOR or promotion of
Foxo1 achieves similar phenotypic outcomes in T cells (and vice-versa). For instance,
Foxo1 activity is critical in the generation of Tregs (650,651) while, conversely, repression
of mTOR also enhances Treg development (703,704). As CD62L and CCR7 are both direct
target genes of Foxo1, activity of Foxo1 is critical for the development of T cell memory
(647,649). On the other hand, repression of mTOR also promotes the formation of
memory (705–707). Consistently, both the repression of mTOR and induction of Foxo1
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enhance the expression of the memory-promoting EOMES transcription factor
(648,649,706).
EOMES, also associating with T cell exhaustion, is likewise promoted by Foxo1 in
chronically stimulated T cells to generate EOMESHIPD-1HI exhausted T cells (631,697).
Conversely, mTOR activity represses the development of T cell exhaustion. For instance,
the Jeff Rathmell Laboratory has recently demonstrated that defective mTORC1 signaling,
alongside metabolic deficiencies, drives T cell exhaustion induced by chronic stimulation
from B cell leukemia (708). Conversely, Staron et al. has shown that rescuing T cells from
exhaustion via αPD-L1 blocking antibody (610) coincides with an increase in mTOR activity
as evidenced by an increase in pS6 expression (631). Moreover, inhibition of mTOR by
rapamycin treatment counteracted the ability of αPD-L1 blockade to improve the
functionality of exhausted T cells (631).
These reports compliment the finding in this thesis that T cells which are less
exhausted via NAC treatment exhibit an enhancement of mTOR activity. However, this
finding must be balanced in interpretation by reports which have demonstrated that
repression of mTOR activity produces a more potent anti-tumor T cell. Rapamycin
treatment has been shown to enhance memory development in T cells (705,706,709).
Moreover, treatment of T cells with rapamycin prior to adoptive transfer enhances the
tumor burden control of the T cells and the conferred survivability of treated mice (706).
However, as rapamycin was originally characterized as a immunosuppressant (710), the
appropriate dosage or schedule for mTOR inhibition can be critical for optimal anti-cancer
benefit. Indeed, prolonging the course of rapamycin treatment in vivo can nullify the
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memory generating benefit of a shorter course dosage schedule (711), inspiring Protul
Shrikant to refer to rapamycin as a “rheostat” for T cell immunotherapy (712). Similarly,
complete ablation of Foxo1 in therapeutic T cells would likely be detrimental to antitumor efficacy as Foxo1-deficient T cells present with defective homeostasis of naïve cells
via impaired IL-7Rα expression and would likely have deficient development of long-term
memory recall responses (646). Therefore, the exhaustion-limiting benefit of Foxo1
attenuation most be balanced against these more severe consequences from the
complete knockout of Foxo1. As such, similar to mTOR, Susan Kaech (the senior author
of Staron, et al.) said that the challenge in quelling T cell exhaustion via Foxo1 repression
is to find the appropriate “sweet point” for optimal benefit (713). Treatment with NAC is
likely a more moderate approach to Foxo1 modulation in comparison with previous
reports which have relied on complete ablation. Moreover, NAC may have pleotropic
effects that may positively counteract the negative consequences of Foxo1 attenuation.
Further studies are needed to determine what effects of NAC are mediated by Foxo1
through the use of NAC treated Foxo1-null cells and/or co-treatment with the Foxo1
inhibitor AS1842856 (714).
There are several mechanisms whereby NAC may potentially modulate Foxo1 and
mTOR expression. NAC could potentially aid Akt in Foxo1 repression by ensuring that the
regulatory cysteines of Akt (Cys296/Cys310) are kept in their reduced form, which is critical
for Akt activation (422). Furthermore, NAC has been shown to increase phospho-ERK
levels during TCR signaling (715). Concurrently, phosphorylation of ERK has been shown
to inversely correlate with the levels of sulfenic acid detected on ERK (716), and ERK
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phosphorylation is blocked when cysteine modifications are prevented with dimedone
treatment (430). Activated Erk has been shown to inactivate tuberous sclerosis 2 (TSC2)
via phosphorylation (717). As TSC2 is a negative regulator of mTOR (718), potential ERK
activation by NAC may facilitate an upregulation in mTOR. Follow-up studies should
determine if NAC modulates the cysteine residues of AKT and if it is involved in ERK
activation.
Beyond an attenuation of the exhausted phenotype, repression of Foxo1 could
also provide an explanation for the enhanced levels of granzyme B observed in this thesis
(Figs. 19, 25) as Foxo1 (and consistently rapamycin) has been demonstrated to repress
granzyme B expression (648,706). Additionally, while we did not observe any modulation
of CD28 or 4-1BB co-stimulatory receptors, from expanding T cells in NAC, there was an
increase in ICOS receptor expression, of which ligation has been shown to repress Foxo1
(644).
Both CCR7 and CD62L are direct target genes of Foxo1, however there was no
observable difference in the expression of these markers between NAC and control
cultured cells. One potential explanation for this inconsistency may be that IL-15, which
was also present in the cultures of rapidly expanding TIL1383I TCR transduced human T
cells, may have bolstered the memory phenotype of the cells independent of modulation
by Foxo1, as IL-15 is critical for the development and maintenance of long lived memory
T cells (719,720). As such, the expression of these markers and other data in this thesis
may have been different or more pronounced if the cells were cultured in IL-2 alone. Both
IL-2 and IL-15 are common γ-chain receptor (CD132) cytokines who both additionally
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share their respective β-chain receptor (CD122) subunits as well (721), differing only in
their “high affinity” receptor subunits IL-2Rα (CD25) and IL-15Rα (CD215) (722). As such,
they both similarly signal through JAK1/3 and STAT3/5 proximal signaling pathways (723).
Both cytokines, being originally described as “growth factors,” do induce the proliferation
of T cells (222,724). However, despite their shared receptor and proximal signaling units,
IL-2 and IL-15 have divergent effects on cultured T cells. IL-2 promotes the differentiation
of effector T cells while also limiting persistence by priming cells to undergo AICD
(343,344). The contribution of IL-2 in limiting T cell persistence is highlighted by the
attenuation of proliferative control in IL-2 deficient mice (725,726).
In contrast, IL-15 protects T cells from AICD, as T cells from IL-15 overexpressing
transgenic mice are resistant to AICD after being primed in IL-2 (357). The enhancement
of durability of T cells by IL-15 is also important for its role in maintaining memory cells as
IL-15 deficient mice have suboptimal levels of memory cells (727). Conversely, IL-2
signaling impedes IL-15 driven memory formation (728) suggesting a diametric influence
over memory development between the two cytokines. Consistently, murine T cells
cultured in IL-15 prior to adoptive transfer preferentially migrate to the lymph nodes of
recipient mice while T cells cultured in IL-2 traffic to sites of induced inflammation (729).
Studies in the Pmel-1 model, demonstrate that IL-15 cultured Pmel-1 cells have a greater
expression of the central memory CD62L and CCR7 lymph-node homing receptors than
cells cultured in parallel in IL-2 (730). Furthermore, IL-15 cultured Pmel-1 cells, while
having reduced in vitro cytolytic functionality, were superior at tumor burden control and
also enhanced the survivability of B16 melanoma challenged mice. As such, the addition
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of IL-15 to the culture medium of TIL1383I transduced TCR transduced T cells may sustain
the expression of CD62L and CCR7 central memory markers even in parallel with a
decrease in Foxo1 expression, which may, in part explain while there was no alteration in
these markers in NAC cultured cells. Studies which have shown expression of these
markers to be influenced by Foxo1 have relied on the complete ablation of Foxo1
(645,649) which does not elucidate the consequence of moderating Foxo1 expression.
Moreover, these studies make no attempt to rescue the central memory phenotype with
IL-15 supplementation. As IL-15 and Foxo1 have contrasting effects on IL-17Rα expression
(731), it is possible they may regulate CCR7 and CD62L expression through independent
mechanisms.
In summation, the data presented in this thesis demonstrate that oxidative stress,
previously defined to be a requisite factor for AICD induced by the TCR restimulation on
activated T cells, augments into the onset of DNA damage as evidenced by an increase in
two DNA damage response markers (H2AX, SMC-1) and subsequent activation of ATM
and p53. These findings suggest an additional layer of regulation which likely escalates
the commitment of an individual T cell to death upon TCR restimulation. Importantly,
protection from DNA damage via culturing cells with NAC, associates with the reduced
susceptibility to AICD and improved killing of melanoma cells both in vitro and in vivo.
Additionally, the in vivo persistence of Pmel-1 cells was improved by NAC culture prior to
adoptive transfer.
Adding NAC to the culture of TIL1383I TCR human transduced T cells benefited the
cells in several ways by a reduction in DNA damage/AICD and T cell exhaustion with a
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concurrent increase in the cytolytic capacity of the T cells (Fig. 37). TIL1383I TCR
transduced cells currently being used in clinical trials were also susceptible to
restimulation induced DNA damage, which was thwarted by both acute and long term
culturing with NAC. Additionally, the addition of NAC to the culture medium during rapid
expansion quelled upregulation of the exhaustion marker PD-1 which was found to be
regulated at the transcriptional level via repression of EOMES and Foxo1. The effect of
NAC on T cells bolsters their effector functionality as evidenced by enhanced control of
tumors as well as the upregulation of granzyme B, likely through counteracting repression
by Foxo1. However, increase in effector functionality does not seem to cause any
decrease in the durability of the cells as evidenced by an increase in vivo persistence.
Together this suggests that the effect of NAC is likely pleiotropic as NAC may enhance
effector functionality, in part through the repression of Foxo1, but also enhances the
persistence of the cell by other mechanisms which merit future investigations.
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Figure 37. Addition of NAC to culture improves the phenotype of rapidly expanded
TIL1383I TCR transduced human T cells via three distinct mechanisms. 1) NAC
increases the antioxidant capacity of T cells as evidenced by an increase in the
expression of surface thiols and a decrease in the detection of the oxidative stress
sensitive dye DCFDA (Fig. 23). As DNA damage caused by TCR restimulation is
dependent on ROS (Fig. 15), TIL1383I TCR transduced human T cells REPed in NAC have
less γH2AX expression when restimulated with MEL624 cells (Fig. 23), and in parallel,
are less susceptible to AICD (Fig. 24). 2) T cells acutely treated with NAC exhibit increase
phosphorylation of AKT and Foxo1 (Fig. 36). As phosphorylation of Foxo1 results in its
nuclear sequestration and ultimately, its proteasomal degradation (640,676), TIL1383I
transduced human T cells REPed in NAC demonstrated a reduction in Foxo1 levels (Fig.
35). The rapid expansion of T cells results in an increase in the exhausted T cell
phenotype [Fig. 33 and ref (170)]. As Foxo1 is upstream of EOMES and PD-1 in the
promotion of the EOMESHIPD-1HI exhausted T cells (631,697), these cells also exhibited
a reduction in both EOMES and PD-1 (Figs 33,34), demonstrating that NAC restrains
development of T cell exhaustion during rapid expansion. 3) As Foxo1 also restrains the
expression of the cytotoxic molecule granzyme B (648), TIL1383I TCR transduced
human T cells expanded in NAC also exhibited an increase In granzyme B (Fig. 26) which
coincided with an increase in the in vitro anti-MEL624 cytotoxic functionality (Fig. 25).
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CHAPTER 6 – MATERIALS AND METHODS

Cells, activation, and culture
All cells were maintained in a humidified incubator (Forma Scientific) at 37°C
supplemented with 5% CO2. Melanoma cell lines (human MEL624 and MEL624-28 and
murine B16 cells) were obtained in 2013 from Drs. Michael Nishimura (Loyola University,
Maywood IL) and Mark Rubinstein (Medical University of South Carolina, Charleston SC).
All cells were periodically verified to be free of mycoplasma contamination using the
MycoAlert Mycoplasma Detection Kit (Lonza) per vender protocol. Additionally, B16 cells
were authenticated and confirmed to be free of rodent pathogens by Dr. Rubinstein.
Normal healthy donor apheresis cells were purchased from Key Biologics, Inc. or
Research Blood Components. Cells from melanoma patients were obtained with consent
as part of an IRB and FDA approved clinical trial (NCT01586403). PBMCs were isolated by
Ficoll density gradient, activated with plate-bound anti-CD3 (5μg/mL, BioLegend
#302902) and anti-CD28 (2µg/mL, BioLegend #317304) for 3 days, washed, and cultured
in Iscove’s Modified Dulbecco’s Medium (Mediatech) supplemented with 10% FBS, 100
IU/mL rIL-2 (Peprotech), and 10ng/mL rIL-15 (Shenandoah), for at least 5 days prior to
TCR restimulation.
For studies using h3T or Pmel transgenic mice obtained from Dr. Shikhar Mehrotra
(Medical University of South Carolina, Charleston SC), splenocytes were prepared into
single-cell suspensions from harvested spleens by mechanical isolation and removal of
red blood cells by incubation with ACK buffer (Gibco) for 1-2 min. Cells are then washed
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through a 70µm cell strainer (Fisher) and cultured in complete media supplemented with
100U/mL recombinant IL-2. Splenocytes from h3T mice were activated with plate-bound
anti-CD3 (1µg/mL, BioLegend #100302) and anti-CD28 (2µg/mL, BioLegend #102102) for
2 days prior to use in assays. Pmel splenocytes were activated with 1µg/mL of gp10025-33
peptide (AnaSpec) with or without supplementation with 10mM N-acetyl cysteine (NAC,
Hospira).

Transduction and rapid expansion of TIL1383I transduced T cells
Transductions of TIL1383I Transduced T cells were performed at the Cell Therapy
Core at Loyola University, Chicago. Isolated PBMCs were activated with 50ng/mL soluble
anti-CD3 (OKT3) for 2-3 days. On the day of transduction, retroviral supernatants were
collected from PG13 1383I A9 retrovirus producing cells and filtered through a 0.45µm
cellulose acetate syringe filter. Filtered virus was then spun onto retronectin coated
plates (30μg/mL) via centrifugation (2000G, 2hrs, 37°C, with no brake). Activated cells
were then added to wells and centrifuged once more (2000G, 2hrs, 37°C, with no brake).
Transduced cells were cultured for several days in AIM-V culture media (supplemented
with 5% human AB serum, 300IU/mL recombinant human IL-,2 and 100ng/mL
recombinant human IL-15) and then purified based on CD34 expression (CliniMACs) using
CD34+ reagent. Subsequently, cells undergo a REP whereby 1x106 transduced cells are
co-cultured with 2x108 irradiated feeder cells supplemented with 30ng/mL anti-CD3.
Cells are left undisturbed for approximately 5 days where media and cytokines are
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replenished and then continued in culture for an additional 5 days for use in assays or
cryopreservation.

Generation of h3T/p53KO mice
The generation of the Trp53 knockout mouse has been described in (658) and is
commercially available from the Jackson Laboratory (Cat# 002101). Trp53 knockout mice
were kindly gifted to us from the laboratory of Dr. Lisa Cunningham (formerly of the Dept
of Pathology, MUSC). The development of the h3T mouse has been described in (660) and
is maintained in the laboratory of our collaborator Dr. Shikhar Mehrotra. Selectively
breeding of H3T+ mice and setting up mating pairs of h3T+/p53 HET and h3T+/p53KO
produced the most even ratio of h3T+/p53WT and h3T+/p53KO offspring. Genotypes were
confirmed via PCR of digested tail clips using primers directed against h3T-α F: 5’TCTCCCGGGCTTCTCACTGCCTAGCC-3’ R: 5’-GTTAAGGGTATAGGATGTTAAGC-3’; h3T-β F:
5’-ATGGGCACAAGGTTGTTCTTCTATGTGGCCCTTTGTCTCC-3’

R:

5’-

GCACTAGACCGCGGGGCTCCGTCTGGATTCCAGCCC-3’ and against p53 WildType: 5’TATACTCAGAGCCGGCCT-3’ AND p53 Knockout (neo): 5’-TCCTCGTCGTTTACGGTATC-3’
(Fig. 38).
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Figure 38. Genotype screening of p53 knockout mice. PCR was performed on tail clip
digestions. PCR product was then evaluated by gel electrophoresis (2% low melting
point agarose). Band indicating p53WT occurs at 430bp and p53KO occurs at 590bp with
both bands occurring for heterozygotes.
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Flow cytometry
Cell surface staining
For the staining of surface markers, cells were removed from assay and washed
twice by pelleting by centrifugation (1,500rpm, 5min, 4°C) and resuspended in FACS
Buffer (PBS w/ 5% FBS, 2mM EDTA, 0.05% NaN3, pH 7.4). Cells were then stained with
fluorochromes per vendor recommended concentration (diluted in FACS Buffer) for 30
min at 4°C protected from light. Subsequently, cells were then washed twice again in
FACS Buffer where they were either acquired or processed further in other staining
protocols.

Annexin staining
Cells were stained as in “Cell Surface Staining” with the exception that after
antibody staining, cells were washed in Annexin V Binding Buffer (10mM HEPES, 140mM
NaCl, 2.5mM CaCl2, pH 7.4). Fluorochrome conjugated Annexin V was then added directly
to flow staining tube 15min prior to acquisition.

Intracellular staining
For the staining of intracellular proteins, cells were initially stained as described in
“Cell Surface Staining.” For the staining of secreted factors such as IFNγ, Protein
Transport Inhibitor Cocktail (500X, eBioscience #00-4980) was added to assay medium at
least 4 hrs prior to termination of experiment. Following surface staining, cells were
processed using the Transcription Factor Staining Buffer Set (eBioscience #00-5523). Cells
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were resuspended in Fixation/Permeabilization reagent and incubated for 20min.
Following incubation, cells were washed twice in Permeabilization Buffer reagent. After
washing, cells were resuspended in Permeabilization Buffer and incubated for 15 min
followed by adding fluorochromes (diluted in Permeabilization Buffer) directly to flow
staining wells/tubes and incubated for 1-2 hrs. Following incubation, cells were then
washed in Permeabilization buffer and then FACS Buffer and then acquired.

Intracellular staining of phospho-specific proteins
For the staining of intracellular phospho-specific proteins, surface stain
fluorochromes were added directly to assay media 20-30min prior to the conclusion of
the assay. At the conclusion of the assay cells were fixed in 2% pre-warmed (37°C)
paraformaldehyde for 20 minutes. Cells were then washed twice in FACS Buffer and then
resuspended in 90% ice-cold methanol for 30min where they were then subsequently
washed and incubated with phospho-specific fluorochromes (diluted in FACS Buffer) for
1-2hrs. Cells were then washed in FACS Buffer and acquired.

Acquisition and analysis
Cells were acquired on either the BD FACS Calibur, BD LSRFortessa, or the BD
Fortessa X-20 cell analyzers in the Flow Cytometry Core of the Hollings Cancer Center.
Analysis was performed using FlowJo Software (Tree Star, Inc.). Cells were first gated
based on Forward-Scatter and Side-Scatter parameters to exclude debris. For human
PBMC experiments, cells were then gated on either CD8+ or CD4+ cells. TIL1383I
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transduced human cells were additionally gated on CD34+ cells. Murine Pmel cells were
gated on Vβ13+CD8+ cells. TRP-1 transduced cells and h3T cells were gated on Vβ14+ or
Vβ12+, respectively, prior to subsequent gating on CD8+ and CD4+ populations.

Amnis ImageStream
For Amnis ImageStream experiments, cells were stained with 250nM MitoTrackerDeepRed (Cell Signal) 30min prior to the conclusion of the assay where they were then
fixed and stained as per “Intracellular Staining of Phospho-Specific Proteins.” Cells were
additionally stained with 250ng/mL Hoechst (Acros Organics) prior to antibody staining.
Samples were acquired on the Amnis ImageStream at the Flow Cytometry Core Facility at
Loyola University, Chicago. At least 10,000 events were acquired. Data were analyzed
using the IDEAS analysis software (Amnis Corporation) using the co-localization module.
Events with a similarity score of ≥1 were defined as positive for co-localization.

Recognition assay
TIL1383I expressing h3T splenocytes (1x105) were co-cultured with 1x105 T2 cells
pulsed with either 1µg/mL hTyr368-376 cognate or Mart-1 irrelevant peptide for 16hrs. At
the conclusion of the assay, cells were pelleted by centrifugation (1500rpm, 5min) and
supernatants were harvested. Supernatants were then assayed to determine the amount
of mouse-IFNγ using the DuoSet ELISA Kit (R&D Systems) according to vendor protocol
and optical density was measured using the FLUOstart OPTIMA plate reader (BMG
Labtech) under the absorbance configuration.
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AICD assay
Cells were previously activated as denoted in “cell culture.” TIL1383I expressing
cells were plated at 2x105 and co-cultured with 1x105 T2 cells pulsed with 1µg/mL hTyr368376

cognate or Mart-1 irrelevant peptide or with HLA-A2+ melanoma cell lines MEL624 or

B16-A2 compared to HLA-A2‒ MEL624-28 or B16 cells as controls. Pmel cells were cocultured with irradiated splenocytes pulsed with 1µg/mL gp10025-33 peptide. TRP-1
transduced cells were co-cultured with irradiated splenocytes pulsed with 4µg/mL TRP-1
peptide. PBMCs were restimulated with 5μg/mL plate-bound anti-CD3. Cells were
restimulated for 4hrs or as indicated in figure legends. Cell death was assessed by
Annexin V staining via flow cytometry.

In vitro cytotoxicity assay
MEL624 and MEL624-28 cells were labeled with 0.1μM and 0.01μM CFSE
(BioLegend) respectively according to vendor protocol. Each labeled cell type melanoma
cell type was co-cultured (2x104 each) with TIL1383I TCR transduced T cells at various
Effector:Target ratios achieved through serial dilution of the T cells. Cells were incubated
overnight and then stained with Annexin V & 7AAD and acquired via flow cytometry.
MEL624 and MEL624-28 cells were gated as either CFSEHI or CFSELO cells and TIL1383I
transduced cells were gated on the CFSE-negative CD34+ population. Cell death was
analyzed as percent Annexin V/7AAD double-positive for each respective population.
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Adoptive cell transfer
All animal experiments were performed with approval by the Institutional Animal
Care and Use Committee at the Medical University of South Carolina. Eight to twelve
week old female C57BL/6 wild type mice (NCI) were subcutaneously injected with 3x105
B16F10 murine melanoma cells. Mice were randomized into treatment groups to ensure
equal distribution in tumor size at initiation of the experiment. One day prior to adoptive
cell transfer, mice were lymphodepleted through total body irradiation (5Gy,
nonmyeloablative). Pmel cells (2x106) or TRP-1 transduced cells cultured in the absence
or presence of 10mM NAC were adoptively transferred via retro-orbital injection. Twice
weekly, tumors were measured using calipers and tumor area (mm2) calculated by
multiplying the length and width of two perpendicular measurements. Mice were
sacrificed when tumor burden reach 400mm2 or when animals exhibited signs of distress.

Biodistribution analysis
Weekly blood samples were collected from the tail vein of mice into a
microcentrifuge tube containing PBS w/ 2mM EDTA to prevent blood clotting. Blood
samples were incubated with ACK buffer for 10 min to lyse Red Blood Cells. Cells were
subsequently washed with PBS and then surface stained for flow cytometric analysis. A
subset of mice where sacrificed on Day 6 post transfer and spleens and tumors were
harvested. Spleens and tumors were processed into single cell suspensions by mechanical
dissociation. Tumors were further digested in 5-10mL of Collagenase II (1mg/mL)
incubated for 1 hr at 37°C with agitation of 250rpm. After incubation, digests were
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washed and resuspended in 3mL of PBS and then gently layered onto 3mL of Histopaque
1083 (Sigma) in 15mL conical tube. Tubes were then centrifuged at 400G for 30min (with
Brake set to ‘1’). Interface layer was then harvested, washed and processed for flow
cytometric analysis.

Statistical methods
For experiments comparing stimulated and unstimulated or NAC treated and
untreated samples from the same donor a two-tailed, paired student t-test was used to
determine significance. Murine studies utilized an unpaired student t-test between
treatment groups. For kinetic studies of expression of markers over a timecourse, a linear
longitudinal regression was calculated utilizing generalized estimating equations with
Wald tests used to calculate p-values between model coefficients at different observed
time points. For murine in vivo studies, kinetics of tumor burden was modeled using
longitudinal linear regression with p-values calculated using a likelihood ratio test based
on a chi-square with 2 degrees of freedom. A log rank test was used to calculate p-value
for differences in survival time. Statistical significance was determined as a p-value < 0.05.
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